<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>Flucelvax Tetra INN-Influenza vaccine (surface antigen inactivated prepared in cell cultures);</title>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
<meta name="generator" content="pdftohtml 0.36"/>
<meta name="author" content="CHMP"/>
<meta name="keywords" content="Flucelvax Tetra INN-Influenza vaccine (surface antigen inactivated prepared in cell cultures);"/>
<meta name="date" content="2023-03-16T15:05:09+00:00"/>
<meta name="subject" content="EPAR"/>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<!-- Page 1 -->
<a name="1"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:12px;font-family:ArialMT;color:#000000;}
	.ft11{font-size:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft12{font-size:17px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page1-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1195px;left:440px;white-space:nowrap" class="ft10">1&#160;</p>
<p style="position:absolute;top:537px;left:412px;white-space:nowrap" class="ft11"><b>ANNEX&#160;I</b>&#160;</p>
<p style="position:absolute;top:575px;left:264px;white-space:nowrap" class="ft11"><b>SUMMARY&#160;OF PRODUCT&#160;CHARACTERISTICS&#160;</b></p>
</div>
<!-- Page 2 -->
<a name="2"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft23{font-size:15px;font-family:ArialMT;color:#000000;}
	.ft24{font-size:17px;font-family:BCDEEE+TimesNewRomanPS;color:#000000;}
	.ft25{font-size:17px;line-height:19px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft26{font-size:17px;line-height:18px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft27{font-size:17px;line-height:15px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft28{font-size:17px;line-height:22px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page2-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft23">&#160;</p>
<p style="position:absolute;top:1195px;left:440px;white-space:nowrap" class="ft20">2&#160;</p>
<p style="position:absolute;top:94px;left:130px;white-space:nowrap" class="ft22">This&#160;medicinal&#160;product&#160;is subject&#160;to additional&#160;monitoring. This will&#160;allow&#160;quick&#160;identification of&#160;</p>
<p style="position:absolute;top:113px;left:106px;white-space:nowrap" class="ft26">new safety&#160;information. Healthcare professionals&#160;are&#160;asked&#160;to&#160;report&#160;any suspected adverse&#160;reactions.&#160;<br/>See section 4.8 for&#160;how&#160;to report&#160;adverse reactions.&#160;<br/>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:189px;left:149px;white-space:nowrap" class="ft21"><b>NAME OF&#160;THE&#160;MEDICINAL&#160;PRODUCT</b>&#160;</p>
<p style="position:absolute;top:208px;left:106px;white-space:nowrap" class="ft26">&#160;<br/>Flucelvax&#160;Tetra&#160;-&#160;suspension for&#160;injection in&#160;pre-filled&#160;syringe&#160;<br/>Influenza&#160;vaccine&#160;(surface&#160;antigen,&#160;inactivated,&#160;prepared in&#160;cell&#160;cultures)&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:303px;left:149px;white-space:nowrap" class="ft21"><b>QUALITATIVE&#160;AND&#160;QUANTITATIVE&#160;COMPOSITION</b>&#160;</p>
<p style="position:absolute;top:322px;left:106px;white-space:nowrap" class="ft25">&#160;<br/>Influenza&#160;virus surface&#160;antigens&#160;(haemagglutinin&#160;and neuraminidase), inactivated,&#160;of&#160;the following&#160;<br/>strains*:&#160;<br/>&#160;<br/>A/Wisconsin/588/2019 (H1N1)pdm09-like strain&#160;(A/Delaware/55/2019 CVR-45)&#160;15&#160;micrograms&#160;<br/>HA**&#160;</p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft22">A/Darwin/6/2021&#160;(H3N2)-like strain&#160;(A/Darwin/11/2021, wild type)&#160;15&#160;micrograms HA**&#160;</p>
<p style="position:absolute;top:473px;left:106px;white-space:nowrap" class="ft22">B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type)&#160;15&#160;micrograms HA**&#160;</p>
<p style="position:absolute;top:501px;left:106px;white-space:nowrap" class="ft28">B/Phuket/3073/2013-like&#160;strain&#160;(B/Singapore/INFTT-16-0610/2016, wild type)&#160;15&#160;micrograms HA**&#160;<br/>&#160;<br/>per&#160;0.5&#160;ml&#160;dose&#160;<br/>……………………………………….&#160;<br/>*&#160;</p>
<p style="position:absolute;top:577px;left:149px;white-space:nowrap" class="ft22">propagated&#160;in Madin Darby&#160;Canine Kidney (MDCK)&#160;cells&#160;</p>
<p style="position:absolute;top:596px;left:106px;white-space:nowrap" class="ft22">**&#160;</p>
<p style="position:absolute;top:596px;left:149px;white-space:nowrap" class="ft22">haemagglutinin&#160;</p>
<p style="position:absolute;top:615px;left:106px;white-space:nowrap" class="ft25">&#160;<br/>The vaccine complies with&#160;the&#160;World Health Organisation (WHO)&#160;recommendation (northern&#160;<br/>hemisphere)&#160;and EU&#160;recommendation&#160;for&#160;the&#160;2022/2023&#160;SEASON.&#160;<br/>&#160;<br/>Flucelvax&#160;Tetra&#160;may&#160;contain traces of&#160;beta-propiolactone, cetyltrimethylammonium&#160;bromide,&#160;and&#160;<br/>polysorbate&#160;80.&#160;&#160;<br/>&#160;<br/>For the full&#160;list&#160;of&#160;excipients, see&#160;section 6.1.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:805px;left:149px;white-space:nowrap" class="ft21"><b>PHARMACEUTICAL&#160;FORM</b>&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft26">&#160;<br/>Suspension&#160;for&#160;injection in&#160;pre-filled syringe&#160;(injection).&#160;<br/>Clear&#160;to&#160;slightly&#160;opalescent&#160;liquid.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:918px;left:149px;white-space:nowrap" class="ft21"><b>CLINICAL&#160;PARTICULARS</b>&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft25">&#160;<br/><b>4.1&#160;</b></p>
<p style="position:absolute;top:956px;left:149px;white-space:nowrap" class="ft21"><b>Therapeutic&#160;indications</b>&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft26">&#160;<br/>Prophylaxis of&#160;influenza in&#160;adults and children&#160;from&#160;2&#160;years of&#160;age.&#160;&#160;<br/>&#160;<br/>Flucelvax&#160;Tetra&#160;should be&#160;used in accordance&#160;with official&#160;recommendations.&#160;<br/>&#160;<br/><b>4.2&#160;</b></p>
<p style="position:absolute;top:1070px;left:149px;white-space:nowrap" class="ft21"><b>Posology and&#160;method of&#160;administration&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft26">&#160;<br/>Posology&#160;<br/>&#160;<br/>Adults and&#160;children&#160;from&#160;2&#160;years of&#160;age:&#160;</p>
</div>
<!-- Page 3 -->
<a name="3"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft39{font-size:10px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft310{font-size:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft311{font-size:17px;line-height:20px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft312{font-size:17px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page3-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft33">&#160;</p>
<p style="position:absolute;top:1195px;left:440px;white-space:nowrap" class="ft30">3&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft35">&#160;<br/>&#160;</p>
<p style="position:absolute;top:133px;left:115px;white-space:nowrap" class="ft31"><b>Age&#160;Group&#160;</b></p>
<p style="position:absolute;top:133px;left:331px;white-space:nowrap" class="ft31"><b>Dose&#160;</b></p>
<p style="position:absolute;top:133px;left:545px;white-space:nowrap" class="ft31"><b>Schedule&#160;</b></p>
<p style="position:absolute;top:162px;left:115px;white-space:nowrap" class="ft32">2&#160;to &lt;&#160;9 years<b>&#160;</b></p>
<p style="position:absolute;top:162px;left:331px;white-space:nowrap" class="ft32">One or&#160;twoa&#160;0.5&#160;mL&#160;doses&#160;</p>
<p style="position:absolute;top:162px;left:545px;white-space:nowrap" class="ft32">If&#160;2 doses, administer&#160;at&#160;least&#160;</p>
<p style="position:absolute;top:186px;left:545px;white-space:nowrap" class="ft32">4 weeks&#160;apart&#160;</p>
<p style="position:absolute;top:215px;left:115px;white-space:nowrap" class="ft32">9&#160;years&#160;of&#160;age&#160;and older<b>&#160;</b></p>
<p style="position:absolute;top:215px;left:331px;white-space:nowrap" class="ft32">One&#160;0.5&#160;mL&#160;dose&#160;</p>
<p style="position:absolute;top:215px;left:545px;white-space:nowrap" class="ft32">Not&#160;applicable&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft36">a&#160;Children&#160;less&#160;than 9&#160;years&#160;of&#160;age who have not&#160;been previously vaccinated against&#160;influenza, should&#160;<br/>receive&#160;a second&#160;dose.&#160;<br/>&#160;<br/>The safety and&#160;efficacy&#160;of&#160;Flucelvax&#160;Tetra&#160;in children&#160;from&#160;birth&#160;to less&#160;than&#160;2&#160;years of&#160;age has not&#160;<br/>been established.&#160;<i>&#160;<br/></i>&#160;<br/>&#160;<br/>Method of&#160;administration&#160;&#160;</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft36">For intramuscular&#160;injection&#160;only.&#160;&#160;<br/>The preferred site&#160;for&#160;injection is the deltoid&#160;muscle of&#160;the upper&#160;arm.&#160;Young children with&#160;<br/>insufficient&#160;deltoid&#160;mass should be vaccinated in the anterolateral&#160;aspect&#160;of&#160;the&#160;thigh.&#160;&#160;<br/>&#160;<br/>The vaccine must&#160;not&#160;be&#160;injected intravenously, subcutaneously or&#160;intradermally and must&#160;not&#160;be&#160;<br/>mixed with other&#160;vaccines&#160;in the&#160;same syringe.&#160;<br/>&#160;<br/>For instructions&#160;on&#160;the&#160;handling of&#160;the&#160;vaccine&#160;before&#160;administration,&#160;see section&#160;6.6.&#160;<br/>&#160;<br/><b>4.3&#160;</b></p>
<p style="position:absolute;top:571px;left:149px;white-space:nowrap" class="ft31"><b>Contraindications</b>&#160;</p>
<p style="position:absolute;top:590px;left:106px;white-space:nowrap" class="ft36">&#160;<br/>Hypersensitivity&#160;to the active substance,&#160;to any of&#160;the&#160;excipients&#160;listed in section&#160;6.1,&#160;or&#160;to possible&#160;<br/>trace&#160;residues&#160;such as&#160;beta-propiolactone, cetyltrimethylammonium&#160;bromide, and&#160;polysorbate&#160;80.&#160;<br/>&#160;<br/><b>4.4&#160;</b></p>
<p style="position:absolute;top:666px;left:149px;white-space:nowrap" class="ft31"><b>Special&#160;warnings&#160;and&#160;precautions&#160;for use&#160;</b></p>
<p style="position:absolute;top:685px;left:106px;white-space:nowrap" class="ft35">&#160;<br/>Traceability&#160;<br/>In order&#160;to&#160;improve the traceability of&#160;biological&#160;medicinal&#160;products,&#160;the name and&#160;the batch number&#160;<br/>of&#160;the administered&#160;product&#160;should be&#160;clearly recorded.&#160;<br/>&#160;<br/>Appropriate&#160;medical&#160;treatment&#160;and supervision&#160;should&#160;always&#160;be&#160;readily available&#160;in case&#160;of&#160;a&#160;rare&#160;<br/>anaphylactic event&#160;following the&#160;administration of&#160;the&#160;vaccine.&#160;<br/>&#160;<br/>Vaccination&#160;should be&#160;postponed&#160;in&#160;patients&#160;with&#160;acute febrile&#160;illness&#160;until&#160;the&#160;fever&#160;is resolved.&#160;&#160;<br/>&#160;<br/>As with&#160;all&#160;injectable&#160;vaccines, Flucelvax&#160;Tetra&#160;must&#160;be administered with caution&#160;to individuals&#160;with&#160;<br/>thrombocytopenia or&#160;a bleeding disorder&#160;since&#160;bleeding may&#160;occur&#160;following an&#160;intramuscular&#160;<br/>administration.&#160;<br/>&#160;<br/>Syncope&#160;(fainting)&#160;can occur&#160;following,&#160;or&#160;even before, any vaccination as&#160;a psychogenic response&#160;to&#160;<br/>the needle injection. This&#160;can be&#160;accompanied by several&#160;neurological&#160;signs such&#160;as&#160;transient&#160;visual&#160;<br/>disturbance, paraesthesia and tonic-clonic limb movements during recovery. It&#160;is&#160;important&#160;that&#160;<br/>procedures&#160;are&#160;in place to&#160;avoid&#160;injury&#160;from&#160;faints.&#160;<br/>&#160;<br/>Antibody response&#160;in patients with&#160;endogenous&#160;or&#160;iatrogenic immunosuppression&#160;may be insufficient&#160;<br/>to prevent&#160;influenza.&#160;<br/>&#160;<br/>A&#160;protective&#160;immune&#160;response&#160;may not&#160;be elicited in all&#160;vaccine&#160;recipients.&#160;<br/>&#160;</p>
</div>
<!-- Page 4 -->
<a name="4"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page4-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft43">&#160;</p>
<p style="position:absolute;top:1195px;left:440px;white-space:nowrap" class="ft40">4&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft41"><b>4.5&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft41"><b>Interaction&#160;with other&#160;medicinal&#160;products and other forms&#160;of&#160;interaction</b>&#160;</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft46">&#160;<br/>No interaction studies&#160;have&#160;been performed&#160;with Flucelvax Tetra.&#160;There are no&#160;data available on co-<br/>administration&#160;of&#160;Flucelvax&#160;Tetra with other&#160;vaccines.&#160;Based on&#160;clinical&#160;experience&#160;with&#160;cell-based&#160;<br/>trivalent&#160;influenza vaccine&#160;(TIVc), Flucelvax Tetra can be given&#160;at&#160;the&#160;same time&#160;as&#160;other&#160;vaccines.&#160;<br/>&#160;<br/><b>4.6&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft41"><b>Fertility, pregnancy and&#160;lactation</b>&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft45">&#160;<br/>Pregnancy&#160;<br/>Inactivated influenza&#160;vaccines, such as Flucelvax Tetra,&#160;can&#160;be&#160;given&#160;in&#160;any&#160;stage&#160;of&#160;pregnancy.&#160;<br/>Larger&#160;safety&#160;datasets are available&#160;on&#160;vaccine&#160;use&#160;during&#160;the&#160;second&#160;or&#160;third trimester, compared with&#160;<br/>the&#160;first&#160;trimester;&#160;however,&#160;data&#160;from&#160;worldwide&#160;use&#160;of&#160;influenza vaccines&#160;do&#160;not&#160;indicate any&#160;<br/>adverse&#160;foetal&#160;and&#160;maternal&#160;outcomes&#160;attributable&#160;to&#160;the vaccine.&#160;<br/>&#160;<br/>A&#160;prospective Pregnancy&#160;Exposure Registry was conducted&#160;in&#160;the United&#160;States&#160;(US) and data were&#160;<br/>collected&#160;from&#160;665 women&#160;vaccinated with Flucelvax&#160;Tetra during&#160;3 Northern Hemisphere&#160;influenza&#160;<br/>seasons (2017-18&#160;to 2019-20), of&#160;whom&#160;28%&#160;were&#160;exposed during their&#160;first&#160;trimester.&#160;Based on&#160;<br/>pregnancy outcomes&#160;and predefined&#160;infant&#160;safety outcomes,&#160;there was no&#160;evidence&#160;of&#160;adverse&#160;foetal,&#160;<br/>newborn or&#160;pregnancy outcomes&#160;attributable&#160;to&#160;the vaccine&#160;during any stage&#160;of&#160;pregnancy.&#160;&#160;<br/>&#160;<br/>There&#160;have&#160;been&#160;no reproductive and developmental&#160;toxicology&#160;studies with&#160;Flucelvax&#160;Tetra.&#160;<br/>Reproductive&#160;and developmental&#160;toxicology&#160;data from&#160;cell-based&#160;trivalent&#160;influenza vaccine&#160;(TIVc)&#160;<br/>do not&#160;predict&#160;an&#160;increased&#160;risk&#160;of&#160;developmental&#160;abnormalities.&#160;<br/>&#160;<br/>Breast-feeding&#160;<br/>It&#160;is unknown&#160;whether&#160;Flucelvax&#160;Tetra&#160;is&#160;excreted in human&#160;milk.&#160;No&#160;effects&#160;on breast&#160;fed&#160;<br/>newborn/infant&#160;are anticipated. Flucelvax Tetra&#160;may be&#160;given&#160;during&#160;lactation.&#160;<br/>&#160;<br/>Fertility&#160;<br/>No human fertility data are&#160;available. Animal&#160;data, with&#160;cell-based trivalent&#160;influenza&#160;vaccine&#160;(TIVc),&#160;<br/>have&#160;not&#160;shown effects&#160;on female&#160;fertility.&#160;Male&#160;fertility has&#160;not&#160;been assessed&#160;in&#160;animals.&#160;<br/>&#160;<br/><b>4.7&#160;</b></p>
<p style="position:absolute;top:696px;left:149px;white-space:nowrap" class="ft41"><b>Effects on&#160;ability&#160;to drive&#160;and&#160;use&#160;machines</b>&#160;</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft46">&#160;<br/>Flucelvax&#160;Tetra&#160;has&#160;no&#160;or&#160;negligible&#160;influence&#160;on the ability&#160;to&#160;drive and use machines.&#160;&#160;<br/>&#160;<br/><b>4.8&#160;</b></p>
<p style="position:absolute;top:772px;left:149px;white-space:nowrap" class="ft41"><b>Undesirable&#160;effects&#160;</b></p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft48">&#160;<br/><i>Summary&#160;of&#160;the safety profile&#160;<br/></i>&#160;<br/>The safety of&#160;Flucelvax Tetra in adults 18 years and&#160;older&#160;was&#160;evaluated&#160;in a&#160;randomised,&#160;controlled&#160;<br/>study&#160;(V130_01),&#160;in which&#160;1334 subjects&#160;received Flucelvax&#160;Tetra.&#160;Similar&#160;rates&#160;of&#160;solicited&#160;local&#160;and&#160;<br/>systemic&#160;adverse&#160;reactions&#160;were reported in&#160;subjects who received Flucelvax Tetra and cell-based&#160;<br/>trivalent&#160;influenza vaccine&#160;comparator&#160;in&#160;this clinical&#160;trial.&#160;<br/>&#160;<br/>The most&#160;commonly&#160;reported (≥10%)&#160;reactions&#160;in&#160;subjects&#160;who received Flucelvax Tetra were pain at&#160;<br/>the&#160;injection&#160;site&#160;(34%), headache (14%),&#160;fatigue&#160;(14%),&#160;myalgia&#160;(14%), erythema&#160;(13%)&#160;and&#160;<br/>induration&#160;(10%).&#160;<br/>&#160;<br/>The&#160;&#160;incidence&#160;&#160;of&#160;&#160;some&#160;&#160;adverse&#160;&#160;reactions&#160;&#160;were&#160;&#160;considerably&#160;&#160;lower&#160;&#160;among&#160;&#160;subjects&#160;≥&#160;65&#160;years&#160;&#160;of&#160;&#160;age&#160;<br/>when compared&#160;to subjects&#160;18&#160;to&#160;&lt;&#160;65 years of&#160;age&#160;(see&#160;table below).&#160;&#160;<br/>&#160;<br/><i>Tabulated&#160;list&#160;of&#160;adverse&#160;reactions</i>&#160;<br/>&#160;<br/>Adverse&#160;reactions&#160;reported&#160;are&#160;listed&#160;according&#160;to&#160;the&#160;following&#160;frequency&#160;categories:&#160;Very&#160;common&#160;<br/>(≥1/10);&#160;Common&#160;(≥1/100&#160;to&#160;&lt;1/10);&#160;Uncommon&#160;(≥1/1,000&#160;to&#160;&lt;1/100),&#160;not&#160;known&#160;(cannot&#160;be&#160;estimated&#160;<br/>from&#160;the available data).&#160;</p>
</div>
<!-- Page 5 -->
<a name="5"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft513{font-size:15px;font-family:TimesNewRomanPS;color:#000000;}
	.ft514{font-size:15px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft515{font-size:15px;font-family:SymbolMT;color:#000000;}
	.ft516{font-size:10px;font-family:TimesNewRomanPS;color:#000000;}
	.ft517{font-size:15px;line-height:18px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft518{font-size:15px;line-height:17px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft519{font-size:15px;line-height:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft520{font-size:15px;line-height:19px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft521{font-size:17px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page5-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft53">&#160;</p>
<p style="position:absolute;top:1195px;left:440px;white-space:nowrap" class="ft50">5&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft55">&#160;<br/><b>Table&#160;1:&#160;&#160;&#160;Adverse&#160;reactions&#160;reported&#160;following&#160;vaccination&#160;in&#160;adults&#160;18 years&#160;and&#160;older&#160;in&#160;</b></p>
<p style="position:absolute;top:127px;left:183px;white-space:nowrap" class="ft51"><b>clinical&#160;trials&#160;and&#160;post-marketing&#160;surveilance.&#160;</b></p>
<p style="position:absolute;top:156px;left:115px;white-space:nowrap" class="ft513"><b>MedDRA&#160;System&#160;Organ class</b>&#160;</p>
<p style="position:absolute;top:156px;left:334px;white-space:nowrap" class="ft513"><b>Very&#160;common</b>&#160;</p>
<p style="position:absolute;top:169px;left:356px;white-space:nowrap" class="ft515">(<b>1/10)</b>&#160;</p>
<p style="position:absolute;top:156px;left:477px;white-space:nowrap" class="ft513"><b>Common</b>&#160;</p>
<p style="position:absolute;top:174px;left:453px;white-space:nowrap" class="ft514">(<b>1/100&#160;to&#160;&lt;1/10)</b>&#160;</p>
<p style="position:absolute;top:156px;left:597px;white-space:nowrap" class="ft517"><b>Uncommon</b>&#160;<br/>(<b>1/1,000&#160;to&#160;</b></p>
<p style="position:absolute;top:191px;left:610px;white-space:nowrap" class="ft513"><b>&lt;1/100)</b>&#160;</p>
<p style="position:absolute;top:156px;left:734px;white-space:nowrap" class="ft513"><b>Frequency&#160;&#160;</b></p>
<p style="position:absolute;top:173px;left:732px;white-space:nowrap" class="ft513"><b>not&#160;known3&#160;</b></p>
<p style="position:absolute;top:216px;left:115px;white-space:nowrap" class="ft513"><b>Immune&#160;system&#160;disorders&#160;</b></p>
<p style="position:absolute;top:216px;left:323px;white-space:nowrap" class="ft514">&#160;</p>
<p style="position:absolute;top:216px;left:451px;white-space:nowrap" class="ft514">&#160;</p>
<p style="position:absolute;top:216px;left:578px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:706px;white-space:nowrap" class="ft518">Allergic&#160;or&#160;<br/>immediate&#160;<br/>hypersensitivity&#160;<br/>reactions,&#160;including&#160;<br/>anaphylactic&#160;shock<b>&#160;</b></p>
<p style="position:absolute;top:304px;left:115px;white-space:nowrap" class="ft519"><b>Metabolism&#160;and&#160;nutrition&#160;<br/>disorders&#160;</b></p>
<p style="position:absolute;top:304px;left:323px;white-space:nowrap" class="ft514">&#160;</p>
<p style="position:absolute;top:304px;left:451px;white-space:nowrap" class="ft514">Loss&#160;of&#160;appetite&#160;</p>
<p style="position:absolute;top:304px;left:578px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:304px;left:706px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:365px;left:115px;white-space:nowrap" class="ft513"><b>Nervous&#160;system&#160;disorders&#160;</b></p>
<p style="position:absolute;top:365px;left:323px;white-space:nowrap" class="ft514">Headache1<b>&#160;</b></p>
<p style="position:absolute;top:365px;left:451px;white-space:nowrap" class="ft514">&#160;</p>
<p style="position:absolute;top:365px;left:578px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:365px;left:706px;white-space:nowrap" class="ft518">Paraesthesia, &#160;<br/>Guillain-Barre&#160;<br/>Syndrome&#160;</p>
<p style="position:absolute;top:425px;left:115px;white-space:nowrap" class="ft513"><b>Gastrointestinal disorders&#160;</b></p>
<p style="position:absolute;top:425px;left:323px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:425px;left:451px;white-space:nowrap" class="ft518">Nausea,&#160;&#160;<br/>Diarrhoea,&#160;&#160;<br/>Vomiting2&#160;</p>
<p style="position:absolute;top:425px;left:578px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:425px;left:706px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:480px;left:115px;white-space:nowrap" class="ft519"><b>Skin and&#160;subcutaneous&#160;tissue&#160;<br/>disorders&#160;</b></p>
<p style="position:absolute;top:480px;left:323px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:480px;left:451px;white-space:nowrap" class="ft514">&#160;</p>
<p style="position:absolute;top:480px;left:578px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:480px;left:706px;white-space:nowrap" class="ft518">Generalised&#160;skin&#160;<br/>reactions&#160;including&#160;<br/>pruritus,&#160;urticaria&#160;or&#160;<br/>non-specific&#160;rash&#160;</p>
<p style="position:absolute;top:550px;left:115px;white-space:nowrap" class="ft519"><b>Musculoskeletal and&#160;<br/>connective&#160;tissue&#160;disorders&#160;</b></p>
<p style="position:absolute;top:550px;left:323px;white-space:nowrap" class="ft514">Myalgia1<b>&#160;</b></p>
<p style="position:absolute;top:550px;left:451px;white-space:nowrap" class="ft514">Arthralgia&#160;</p>
<p style="position:absolute;top:550px;left:578px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:550px;left:706px;white-space:nowrap" class="ft513"><b>&#160;</b></p>
<p style="position:absolute;top:624px;left:115px;white-space:nowrap" class="ft519"><b>General disorders&#160;and&#160;<br/>administration site&#160;conditions&#160;</b></p>
<p style="position:absolute;top:624px;left:323px;white-space:nowrap" class="ft518">Injection&#160;site&#160;pain,&#160;<br/>Fatigue1,&#160;&#160;<br/>Erythema,&#160;<br/>Induration1&#160;&#160;</p>
<p style="position:absolute;top:624px;left:451px;white-space:nowrap" class="ft518">Ecchymosis,&#160;&#160;<br/>Chills&#160;</p>
<p style="position:absolute;top:625px;left:578px;white-space:nowrap" class="ft514">Fever&#160;(≥&#160;38C)<b>&#160;</b></p>
<p style="position:absolute;top:624px;left:706px;white-space:nowrap" class="ft518">Extensive&#160;swelling&#160;<br/>of&#160;injected&#160;limb&#160;&#160;&#160;</p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft55">1&#160;Reported&#160;as Common&#160;in&#160;the&#160;elderly&#160;population&#160;65&#160;years&#160;of&#160;age&#160;and&#160;older&#160;<br/>2&#160;Reported&#160;as Uncommon&#160;in&#160;the&#160;elderly&#160;population&#160;65&#160;years&#160;of&#160;age&#160;and&#160;older&#160;<br/>3&#160;Adverse&#160;reactions&#160;reported&#160;from&#160;post-marketing&#160;surveillance&#160;<br/>&#160;<br/>Paediatric&#160;population&#160;(2&#160;to&#160;less&#160;than 18&#160;years&#160;of&#160;age)<b>&#160;<br/></b>&#160;<br/>The safety of&#160;Flucelvax Tetra in children&#160;2&#160;to&#160;less&#160;than&#160;18 years of&#160;age&#160;has&#160;been&#160;evaluated&#160;in&#160;two&#160;<br/>clinical&#160;studies, V130_03 and V130_12. In&#160;the&#160;randomised,&#160;controlled study V130_03,&#160;&#160;1159&#160;<br/>paediatric subjects&#160;received&#160;Flucelvax Tetra&#160;(584&#160;subjects 9&#160;to&#160;&lt;18 years;&#160;575 subjects&#160;4 to&#160;&lt;9 years).&#160;<br/>Children 9&#160;to&#160;less than 18&#160;years&#160;of&#160;age&#160;received a single dose&#160;of&#160;Flucelvax Tetra.&#160;Children 4&#160;to&#160;less&#160;<br/>than 9&#160;years of&#160;age received one or&#160;two doses (separated by 4 weeks)&#160;of&#160;Flucelvax Tetra based on&#160;<br/>determination of&#160;the subject’s&#160;prior&#160;influenza&#160;vaccination history. In this&#160;age&#160;group, 235 paediatric&#160;<br/>subjects received&#160;one dose&#160;and 340&#160;subjects received two doses.&#160;Similar&#160;rates of&#160;solicited&#160;local&#160;and&#160;<br/>systemic&#160;adverse&#160;reactions&#160;were reported in&#160;subjects who received Flucelvax Tetra and cell-based&#160;<br/>trivalent&#160;influenza vaccine&#160;comparator&#160;in&#160;this clinical&#160;trial.&#160;<br/>&#160;&#160;<br/>In the multinational,&#160;randomised, observer-blind study&#160;V130_12,&#160;the safety population included&#160;a total&#160;<br/>of&#160;2255&#160;children 2&#160;to&#160;less than 18 years of&#160;age&#160;who&#160;received Flucelvax Tetra&#160;(580 subjects 2&#160;to &lt;&#160;6&#160;<br/>years;&#160;564 subjects&#160;6 to&#160;&lt; 9&#160;years;&#160;1111 subjects 9&#160;to &lt;&#160;18 years). Children 9&#160;to&#160;less than 18 years of&#160;<br/>age&#160;received&#160;a single dose&#160;of&#160;Flucelvax Tetra. Children 2 to&#160;less than 9 years of&#160;age received one or&#160;<br/>two doses&#160;(separated&#160;by 28&#160;days)&#160;of&#160;Flucelvax Tetra&#160;based on determination of&#160;the&#160;subject’s prior&#160;<br/>influenza&#160;vaccination history.&#160;<br/>&#160;<br/>&#160;</p>
</div>
<!-- Page 6 -->
<a name="6"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page6-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft63">&#160;</p>
<p style="position:absolute;top:1195px;left:440px;white-space:nowrap" class="ft60">6&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft65">The most&#160;common local&#160;and systemic&#160;adverse reactions&#160;reported&#160;in&#160;either&#160;study&#160;is&#160;described below&#160;by&#160;<br/>paediatric&#160;sub-group.&#160;<br/>&#160;<br/>The most&#160;common (≥10%)&#160;local&#160;and systemic&#160;adverse&#160;reactions&#160;after&#160;one dose&#160;reported in&#160;paediatric&#160;<br/>subjects of&#160;9 to&#160;&lt;&#160;18 years&#160;of&#160;age were&#160;injection site pain&#160;(58%), headache&#160;(22%), erythema&#160;(19%),&#160;<br/>fatigue&#160;(18%), myalgia&#160;(16%),&#160;and&#160;induration&#160;(15%).&#160;&#160;<br/>&#160;<br/>The most&#160;common (≥10%)&#160;local&#160;and systemic&#160;adverse&#160;reactions&#160;after&#160;any vaccination&#160;in children&#160;6 to&#160;<br/>less&#160;than 9 years of&#160;age&#160;were pain at&#160;the injection site (61%), injection site&#160;erythema&#160;(25%),&#160;injection&#160;<br/>site&#160;induration&#160;(19%),&#160;fatigue (16%), headache (16%)&#160;and injection site ecchymosis (11%).&#160;&#160;<br/>&#160;<br/>The most&#160;common (≥10%)&#160;local&#160;and systemic adverse&#160;reactions&#160;after&#160;any vaccination in children&#160;2 to&#160;<br/>less&#160;than 6 years of&#160;age&#160;were tenderness&#160;at&#160;the&#160;injection&#160;site (54%), injection&#160;site&#160;erythema&#160;(23%),&#160;<br/>sleepiness&#160;(21%),&#160;irritability (19%),&#160;injection site&#160;induration&#160;(15%),&#160;change in eating habits&#160;(14%)&#160;and&#160;<br/>injection&#160;site ecchymosis&#160;(11%).&#160;&#160;<br/>&#160;<br/>Compared&#160;to&#160;adults&#160;18&#160;years&#160;of&#160;age&#160;and&#160;older,&#160;paediatric&#160;subjects&#160;generally&#160;reported&#160;higher&#160;rates&#160;of&#160;local&#160;<br/>and&#160;systemic adverse&#160;reactions.&#160;<br/>&#160;<br/>In&#160;children&#160;who&#160;received&#160;a&#160;second&#160;dose&#160;of&#160;Flucelvax&#160;Tetra&#160;the&#160;incidence&#160;of&#160;adverse&#160;reactions&#160;following&#160;<br/>the second dose of&#160;vaccine&#160;was&#160;similar&#160;or&#160;slightly lower&#160;to&#160;that&#160;observed with&#160;the&#160;first&#160;dose.&#160;<br/>&#160;<br/>The frequency of&#160;adverse&#160;reactions in children 2 to less and 18 years of&#160;age&#160;in these&#160;clinical&#160;studies&#160;are&#160;<br/>described&#160;in Table 2&#160;below.&#160;</p>
</div>
<!-- Page 7 -->
<a name="7"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft722{font-size:18px;font-family:TimesNewRomanPS;color:#000000;}
	.ft723{font-size:17px;font-family:TimesNewRomanPSMT;color:#0000ff;}
	.ft724{font-size:18px;line-height:20px;font-family:TimesNewRomanPS;color:#000000;}
	.ft725{font-size:10px;line-height:17px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page7-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft73">&#160;</p>
<p style="position:absolute;top:1195px;left:440px;white-space:nowrap" class="ft70">7&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft724"><b>Table&#160;2:&#160;Solicited&#160;adverse&#160;reactions reported&#160;in&#160;clinical&#160;studies&#160;in&#160;children&#160;2 to &lt;&#160;18&#160;<br/>years&#160;of age&#160;</b></p>
<p style="position:absolute;top:187px;left:131px;white-space:nowrap" class="ft713"><b>MedDRA&#160;System&#160;</b></p>
<p style="position:absolute;top:204px;left:149px;white-space:nowrap" class="ft713"><b>Organ class</b>&#160;</p>
<p style="position:absolute;top:162px;left:297px;white-space:nowrap" class="ft713"><b>Adverse&#160;Reactions&#160;</b></p>
<p style="position:absolute;top:153px;left:577px;white-space:nowrap" class="ft713"><b>Frequency&#160;</b></p>
<p style="position:absolute;top:170px;left:611px;white-space:nowrap" class="ft713"><b>&#160;</b></p>
<p style="position:absolute;top:226px;left:356px;white-space:nowrap" class="ft713"><b>&#160;</b></p>
<p style="position:absolute;top:210px;left:510px;white-space:nowrap" class="ft713"><b>2&#160;to&#160;&lt;&#160;9&#160;years</b>&#160;</p>
<p style="position:absolute;top:226px;left:671px;white-space:nowrap" class="ft713"><b>9&#160;to&#160;&lt;&#160;18&#160;years</b>&#160;</p>
<p style="position:absolute;top:243px;left:472px;white-space:nowrap" class="ft713"><b>2&#160;to&#160;&lt;&#160;6&#160;1&#160;</b></p>
<p style="position:absolute;top:243px;left:584px;white-space:nowrap" class="ft713"><b>6&#160;to&#160;&lt;9&#160;</b></p>
<p style="position:absolute;top:272px;left:134px;white-space:nowrap" class="ft713"><b>Metabolism&#160;and&#160;</b></p>
<p style="position:absolute;top:290px;left:126px;white-space:nowrap" class="ft713"><b>nutrition disorders&#160;</b></p>
<p style="position:absolute;top:281px;left:308px;white-space:nowrap" class="ft714">Loss&#160;of&#160;appetite&#160;</p>
<p style="position:absolute;top:281px;left:487px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:281px;left:563px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:281px;left:690px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:316px;left:136px;white-space:nowrap" class="ft713"><b>Nervous&#160;system&#160;</b></p>
<p style="position:absolute;top:333px;left:156px;white-space:nowrap" class="ft713"><b>disorders&#160;</b></p>
<p style="position:absolute;top:325px;left:327px;white-space:nowrap" class="ft714">Headache&#160;</p>
<p style="position:absolute;top:325px;left:487px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:325px;left:563px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:325px;left:675px;white-space:nowrap" class="ft714">Very&#160;common&#160;&#160;</p>
<p style="position:absolute;top:376px;left:135px;white-space:nowrap" class="ft713"><b>Gastrointestinal&#160;</b></p>
<p style="position:absolute;top:393px;left:156px;white-space:nowrap" class="ft713"><b>disorders&#160;</b></p>
<p style="position:absolute;top:358px;left:326px;white-space:nowrap" class="ft714">Diarrhoea&#160;</p>
<p style="position:absolute;top:358px;left:472px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:358px;left:578px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:358px;left:690px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:384px;left:334px;white-space:nowrap" class="ft714">Nausea&#160;</p>
<p style="position:absolute;top:384px;left:487px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:384px;left:578px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:384px;left:690px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:410px;left:327px;white-space:nowrap" class="ft714">Vomiting&#160;</p>
<p style="position:absolute;top:410px;left:472px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:410px;left:578px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:410px;left:690px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:430px;left:121px;white-space:nowrap" class="ft713"><b>Musculoskeletal and&#160;</b></p>
<p style="position:absolute;top:447px;left:133px;white-space:nowrap" class="ft713"><b>connective&#160;tissue&#160;</b></p>
<p style="position:absolute;top:464px;left:156px;white-space:nowrap" class="ft713"><b>disorders&#160;</b></p>
<p style="position:absolute;top:432px;left:327px;white-space:nowrap" class="ft714">Myalgia&#160;2&#160;</p>
<p style="position:absolute;top:431px;left:486px;white-space:nowrap" class="ft72">N/A&#160;</p>
<p style="position:absolute;top:432px;left:563px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:432px;left:675px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:458px;left:326px;white-space:nowrap" class="ft714">Arthralgia&#160;</p>
<p style="position:absolute;top:458px;left:487px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:458px;left:578px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:458px;left:690px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:577px;left:129px;white-space:nowrap" class="ft713"><b>General disorders&#160;</b></p>
<p style="position:absolute;top:594px;left:125px;white-space:nowrap" class="ft713"><b>and&#160;administration&#160;</b></p>
<p style="position:absolute;top:611px;left:141px;white-space:nowrap" class="ft713"><b>site&#160;conditions&#160;</b></p>
<p style="position:absolute;top:484px;left:284px;white-space:nowrap" class="ft714">Injection&#160;site&#160;tenderness&#160;</p>
<p style="position:absolute;top:484px;left:457px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:484px;left:593px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:484px;left:705px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:506px;left:302px;white-space:nowrap" class="ft714">Injection&#160;site&#160;pain&#160;</p>
<p style="position:absolute;top:506px;left:487px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:506px;left:563px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:506px;left:675px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:528px;left:288px;white-space:nowrap" class="ft714">Injection&#160;site&#160;erythema&#160;</p>
<p style="position:absolute;top:528px;left:457px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:528px;left:563px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:528px;left:675px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:550px;left:282px;white-space:nowrap" class="ft714">Injections&#160;site&#160;induration&#160;</p>
<p style="position:absolute;top:550px;left:457px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:550px;left:563px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:550px;left:675px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:572px;left:281px;white-space:nowrap" class="ft714">Injection&#160;site&#160;ecchymosis&#160;</p>
<p style="position:absolute;top:572px;left:457px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:572px;left:561px;white-space:nowrap" class="ft714">Very&#160;Common&#160;</p>
<p style="position:absolute;top:572px;left:688px;white-space:nowrap" class="ft714">&#160;Common&#160;</p>
<p style="position:absolute;top:594px;left:325px;white-space:nowrap" class="ft714">Sleepiness&#160;</p>
<p style="position:absolute;top:594px;left:457px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:594px;left:593px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:594px;left:705px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:616px;left:325px;white-space:nowrap" class="ft714">Irritability&#160;</p>
<p style="position:absolute;top:616px;left:457px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:616px;left:593px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:616px;left:705px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:638px;left:334px;white-space:nowrap" class="ft714">Fatigue&#160;</p>
<p style="position:absolute;top:638px;left:487px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:638px;left:563px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:638px;left:675px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:660px;left:286px;white-space:nowrap" class="ft714">Change&#160;in&#160;eating&#160;habits&#160;</p>
<p style="position:absolute;top:660px;left:457px;white-space:nowrap" class="ft714">Very&#160;common&#160;</p>
<p style="position:absolute;top:660px;left:593px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:660px;left:705px;white-space:nowrap" class="ft714">N/A&#160;</p>
<p style="position:absolute;top:682px;left:307px;white-space:nowrap" class="ft714">Chills/Shivering&#160;</p>
<p style="position:absolute;top:682px;left:472px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:682px;left:578px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:682px;left:690px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:701px;left:311px;white-space:nowrap" class="ft714">Fever&#160;(≥38° C)&#160;</p>
<p style="position:absolute;top:704px;left:472px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:704px;left:578px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:704px;left:690px;white-space:nowrap" class="ft714">Common&#160;</p>
<p style="position:absolute;top:722px;left:106px;white-space:nowrap" class="ft75">1&#160;The&#160;youngest age&#160;range&#160;in&#160;study&#160;V130_03&#160;was 4&#160;to&#160;&lt;&#160;6&#160;years&#160;&#160;<br/>2&#160;Myalgia&#160;reported&#160;with&#160;a&#160;frequency&#160;of&#160;Common&#160;(3%&#160;and&#160;6%)&#160;in&#160;children&#160;6&#160;to&#160;&lt;&#160;9&#160;and&#160;9&#160;to&#160;&lt;&#160;18&#160;years,&#160;respectively,&#160;<br/>in&#160;study&#160;V130_12&#160;&#160;&#160;<br/>&#160;<br/>&#160;<br/>Reporting&#160;of&#160;suspected adverse&#160;reactions&#160;<br/>Reporting&#160;suspected adverse reactions after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important. It&#160;<br/>allows continued&#160;monitoring of&#160;the benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;<br/>professionals&#160;are&#160;asked to report&#160;any&#160;suspected adverse reactions via&#160;the national&#160;reporting system&#160;<br/>listed&#160;i<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">n&#160;Appendix V.</a>&#160;<br/>&#160;<br/><b>4.9&#160;</b></p>
<p style="position:absolute;top:930px;left:149px;white-space:nowrap" class="ft71"><b>Overdose</b>&#160;</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft75">&#160;<br/>There&#160;are&#160;no data&#160;for&#160;overdose&#160;with Flucelvax&#160;Tetra.&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:1025px;left:149px;white-space:nowrap" class="ft71"><b>PHARMACOLOGICAL&#160;PROPERTIES</b>&#160;</p>
<p style="position:absolute;top:1044px;left:106px;white-space:nowrap" class="ft76">&#160;<br/><b>5.1&#160;&#160;&#160;Pharmacodynamic properties</b>&#160;<br/>&#160;<br/>Pharmacotherapeutic group:&#160;Influenza vaccine, ATC&#160;code:&#160;J07BB02&#160;<br/>&#160;<br/>Mechanism&#160;of&#160;action&#160;<br/>&#160;</p>
</div>
<!-- Page 8 -->
<a name="8"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft826{font-size:15px;font-family:TimesNewRomanPS;color:#000000;-moz-transform: matrix(-0.000000044, -0.999999956, 0.999999956, -0.000000044, 0, 0);-webkit-transform: matrix(-0.000000044, -0.999999956, 0.999999956, -0.000000044, 0, 0);-o-transform: matrix(-0.000000044, -0.999999956, 0.999999956, -0.000000044, 0, 0);-ms-transform: matrix(-0.000000044, -0.999999956, 0.999999956, -0.000000044, 0, 0);-moz-transform-origin: left 75%;-webkit-transform-origin: left 75%;-o-transform-origin: left 75%;-ms-transform-origin: left 75%;}
-->
</style>
<div id="page8-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft83">&#160;</p>
<p style="position:absolute;top:1195px;left:440px;white-space:nowrap" class="ft80">8&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft85">Flucelvax&#160;Tetra&#160;provides active immunisation&#160;against&#160;four&#160;influenza&#160;virus strains&#160;(two A&#160;subtypes and&#160;<br/>two B&#160;types)&#160;contained&#160;in&#160;the vaccine. Flucelvax Tetra&#160;induces&#160;humoral&#160;antibodies against&#160;the&#160;<br/>haemagglutinins. These&#160;antibodies&#160;neutralise&#160;influenza&#160;viruses.&#160;<br/>&#160;<br/>Flucelvax&#160;Tetra&#160;is&#160;manufactured using&#160;Madin Darby Canine&#160;Kidney (MDCK)&#160;cells.&#160;<br/>&#160;<br/>Specific levels of&#160;haemagglutination&#160;inhibition (HI)&#160;antibody&#160;titres&#160;post-vaccination with&#160;inactivated&#160;<br/>influenza&#160;vaccine have&#160;not&#160;been correlated with protection&#160;from&#160;influenza&#160;virus. In some human&#160;<br/>studies,&#160;antibody titres&#160;of&#160;1:40 or&#160;greater&#160;have been associated with&#160;protection from&#160;influenza illness in&#160;<br/>up to 50%&#160;of&#160;subjects.&#160;<br/>&#160;<br/>Antibody against&#160;one influenza&#160;virus type or&#160;subtype&#160;confers&#160;limited&#160;or&#160;no&#160;protection against&#160;another.&#160;<br/>Furthermore,&#160;antibody&#160;to one antigenic variant&#160;of&#160;influenza virus&#160;might&#160;not&#160;protect&#160;against&#160;a&#160;new&#160;<br/>antigenic variant&#160;of&#160;the&#160;same type or&#160;subtype.&#160;&#160;<br/>&#160;<br/>Annual&#160;revaccination&#160;with&#160;current&#160;influenza&#160;vaccines&#160;is recommended because&#160;immunity declines&#160;<br/>during the year&#160;after&#160;vaccination and&#160;circulating strains&#160;of&#160;influenza virus&#160;may&#160;change from&#160;year&#160;to&#160;<br/>year.&#160;<br/>&#160;<br/>Pharmacodynamic effects&#160;<br/>&#160;<br/><i>Immunogenicity&#160;of&#160;Flucelvax Tetra</i>&#160;<i>in Adults&#160;18 years&#160;of&#160;age&#160;and older&#160;</i></p>
<p style="position:absolute;top:515px;left:106px;white-space:nowrap" class="ft86">Immunogenicity of&#160;Flucelvax Tetra&#160;was evaluated in&#160;adults 18 years of&#160;age&#160;and older&#160;in a&#160;randomised,&#160;<br/>double-blind, controlled study&#160;(V130_01). In&#160;this study, subjects received&#160;Flucelvax Tetra&#160;(N&#160;=&#160;1334)&#160;<br/>or&#160;one&#160;of&#160;the&#160;two formulations of&#160;comparator&#160;cell-based&#160;trivalent&#160;influenza&#160;vaccine (TIVc)&#160;[TIV1c&#160;<br/>(N&#160;=&#160;677)&#160;or&#160;TIV2c&#160;(N&#160;=&#160;669)].&#160;The&#160;immune response&#160;to each of&#160;the vaccine antigens&#160;was&#160;assessed,&#160;<br/>21&#160;days&#160;after&#160;vaccination.&#160;<br/>&#160;<br/>The immunogenicity endpoints were geometric&#160;mean antibody&#160;titres (GMTs)&#160;of&#160;haemagglutination&#160;<br/>inhibition&#160;(HI)&#160;antibodies&#160;response and&#160;percentage of&#160;subjects who achieved seroconversions, defined&#160;<br/>as&#160;a pre-vaccination HI&#160;titre&#160;of&#160;&lt;1:10 with&#160;a post&#160;vaccination&#160;titre&#160;≥1:40 or&#160;with a&#160;pre-vaccination HI&#160;<br/>titre&#160;of&#160;≥10&#160;and a&#160;minimum&#160;4-fold&#160;increase&#160;in serum&#160;HI&#160;antibody titre.&#160;<br/>&#160;<br/>Flucelvax&#160;Tetra&#160;was non-inferior&#160;to TIVc. Non-inferiority was established&#160;for&#160;all&#160;4&#160;influenza&#160;strains&#160;<br/>included&#160;in&#160;Flucelvax Tetra, as&#160;assessed&#160;by ratios of&#160;GMTs and the differences in&#160;the percentages&#160;of&#160;<br/>subjects achieving&#160;seroconversion&#160;at&#160;3 weeks&#160;following vaccination. The&#160;antibody&#160;response&#160;to&#160;<br/>influenza&#160;B&#160;strains contained in&#160;Flucelvax Tetra&#160;was superior&#160;to the antibody&#160;response&#160;after&#160;<br/>vaccination&#160;with TIVc&#160;containing an&#160;influenza&#160;B&#160;strain&#160;from&#160;the alternate lineage.&#160;There was no&#160;<br/>evidence&#160;that&#160;the addition of&#160;the second&#160;influenza&#160;B&#160;strain&#160;resulted&#160;in immune&#160;interference&#160;to other&#160;<br/>strains included&#160;in the vaccine.&#160;<br/>&#160;<br/>Age subgroup&#160;analyses in&#160;subjects&#160;18 to less&#160;than&#160;65 years&#160;of&#160;age&#160;and 65 years of&#160;age&#160;and above&#160;<br/>confirmed&#160;that&#160;HI&#160;antibody&#160;responses (GMT&#160;and differences&#160;in vaccine&#160;group seroconversion rates)&#160;<br/>met&#160;non-inferiority&#160;immunogenicity criteria&#160;3 weeks following vaccination for&#160;all&#160;4 influenza&#160;strains&#160;<br/>in both&#160;age groups.&#160;<br/>&#160;<br/>The non-inferiority data observed are summarised&#160;in Table&#160;3.&#160;<br/>&#160;<br/><b>Table&#160;3:&#160;&#160;&#160;Noninferiority of&#160;Flucelvax Tetra&#160;relative&#160;to TIVc&#160;in adults 18&#160;years&#160;of&#160;age and&#160;above&#160;</b></p>
<p style="position:absolute;top:1025px;left:183px;white-space:nowrap" class="ft81"><b>–&#160;Per&#160;protocol&#160;analysis&#160;set&#160;(V130_01)&#160;</b></p>
<p style="position:absolute;top:1056px;left:115px;white-space:nowrap" class="ft813"><b>&#160;</b></p>
<p style="position:absolute;top:1108px;left:214px;white-space:nowrap" class="ft813"><b>&#160;</b></p>
<p style="position:absolute;top:1074px;left:292px;white-space:nowrap" class="ft813"><b>Flucelvax&#160;Tetra&#160;</b></p>
<p style="position:absolute;top:1091px;left:314px;white-space:nowrap" class="ft813"><b>N&#160;=&#160;1250&#160;</b></p>
<p style="position:absolute;top:1074px;left:421px;white-space:nowrap" class="ft813"><b>TIV1c/TIV2ca&#160;</b></p>
<p style="position:absolute;top:1091px;left:415px;white-space:nowrap" class="ft813"><b>N&#160;=&#160;635/N&#160;=&#160;639&#160;</b></p>
<p style="position:absolute;top:1065px;left:553px;white-space:nowrap" class="ft813"><b>Vaccine&#160;Group&#160;</b></p>
<p style="position:absolute;top:1082px;left:584px;white-space:nowrap" class="ft813"><b>Ratio&#160;</b></p>
<p style="position:absolute;top:1099px;left:571px;white-space:nowrap" class="ft813"><b>(95%&#160;CI)&#160;</b></p>
<p style="position:absolute;top:1056px;left:706px;white-space:nowrap" class="ft813"><b>Vaccine&#160;</b></p>
<p style="position:absolute;top:1074px;left:710px;white-space:nowrap" class="ft813"><b>Group&#160;</b></p>
<p style="position:absolute;top:1091px;left:698px;white-space:nowrap" class="ft813"><b>Difference&#160;</b></p>
<p style="position:absolute;top:1108px;left:701px;white-space:nowrap" class="ft813"><b>(95%&#160;CI)&#160;</b></p>
<p style="position:absolute;top:1137px;left:129px;white-space:nowrap" class="ft826"><b>A/</b></p>
<p style="position:absolute;top:1135px;left:147px;white-space:nowrap" class="ft826"><b>H</b></p>
<p style="position:absolute;top:1133px;left:165px;white-space:nowrap" class="ft826"><b>1</b></p>
<p style="position:absolute;top:1135px;left:182px;white-space:nowrap" class="ft826"><b>N</b></p>
<p style="position:absolute;top:1133px;left:200px;white-space:nowrap" class="ft826"><b>1</b></p>
<p style="position:absolute;top:1126px;left:200px;white-space:nowrap" class="ft826"><b>&#160;</b>GMT&#160;</p>
<p style="position:absolute;top:1143px;left:186px;white-space:nowrap" class="ft814">(95% CI)&#160;</p>
<p style="position:absolute;top:1126px;left:326px;white-space:nowrap" class="ft814">302.8&#160;</p>
<p style="position:absolute;top:1143px;left:301px;white-space:nowrap" class="ft814">(281.8-325.5)&#160;</p>
<p style="position:absolute;top:1126px;left:450px;white-space:nowrap" class="ft814">298.9&#160;</p>
<p style="position:absolute;top:1143px;left:426px;white-space:nowrap" class="ft814">(270.3-330.5)&#160;</p>
<p style="position:absolute;top:1126px;left:592px;white-space:nowrap" class="ft814">1.0&#160;</p>
<p style="position:absolute;top:1143px;left:575px;white-space:nowrap" class="ft814">(0.9-<b>1.1</b>)&#160;</p>
<p style="position:absolute;top:1135px;left:728px;white-space:nowrap" class="ft814">-&#160;</p>
</div>
<!-- Page 9 -->
<a name="9"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft927{font-size:15px;line-height:15px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft928{font-size:17px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page9-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft93">&#160;</p>
<p style="position:absolute;top:1195px;left:440px;white-space:nowrap" class="ft90">9&#160;</p>
<p style="position:absolute;top:90px;left:168px;white-space:nowrap" class="ft914">Seroconversion&#160;</p>
<p style="position:absolute;top:107px;left:168px;white-space:nowrap" class="ft914">Rateb&#160;(95% CI)&#160;</p>
<p style="position:absolute;top:90px;left:323px;white-space:nowrap" class="ft914">49.2%&#160;</p>
<p style="position:absolute;top:107px;left:309px;white-space:nowrap" class="ft914">(46.4-52.0)&#160;</p>
<p style="position:absolute;top:90px;left:447px;white-space:nowrap" class="ft914">48.7%&#160;</p>
<p style="position:absolute;top:107px;left:433px;white-space:nowrap" class="ft914">(44.7-52.6)&#160;</p>
<p style="position:absolute;top:98px;left:599px;white-space:nowrap" class="ft914">-&#160;</p>
<p style="position:absolute;top:90px;left:713px;white-space:nowrap" class="ft914">-0.5%&#160;</p>
<p style="position:absolute;top:107px;left:702px;white-space:nowrap" class="ft914">(-5.3-<b>4.2</b>)&#160;</p>
<p style="position:absolute;top:172px;left:134px;white-space:nowrap" class="ft926"><b>A/H</b></p>
<p style="position:absolute;top:146px;left:134px;white-space:nowrap" class="ft926"><b>3</b></p>
<p style="position:absolute;top:138px;left:134px;white-space:nowrap" class="ft926"><b>N2</b></p>
<p style="position:absolute;top:120px;left:134px;white-space:nowrap" class="ft926"><b>&#160;</b></p>
<p style="position:absolute;top:125px;left:198px;white-space:nowrap" class="ft914">GMT&#160;</p>
<p style="position:absolute;top:142px;left:186px;white-space:nowrap" class="ft914">(95% CI)&#160;</p>
<p style="position:absolute;top:125px;left:326px;white-space:nowrap" class="ft914">372.3&#160;</p>
<p style="position:absolute;top:142px;left:301px;white-space:nowrap" class="ft914">(349.2-396.9)&#160;</p>
<p style="position:absolute;top:125px;left:450px;white-space:nowrap" class="ft914">378.4&#160;</p>
<p style="position:absolute;top:142px;left:426px;white-space:nowrap" class="ft914">(345.1-414.8)&#160;</p>
<p style="position:absolute;top:125px;left:592px;white-space:nowrap" class="ft914">1.0&#160;</p>
<p style="position:absolute;top:142px;left:575px;white-space:nowrap" class="ft914">(0.9-<b>1.1</b>)&#160;</p>
<p style="position:absolute;top:133px;left:728px;white-space:nowrap" class="ft914">-&#160;</p>
<p style="position:absolute;top:160px;left:168px;white-space:nowrap" class="ft914">Seroconversion&#160;</p>
<p style="position:absolute;top:177px;left:168px;white-space:nowrap" class="ft914">Rateb&#160;(95% CI)&#160;</p>
<p style="position:absolute;top:160px;left:323px;white-space:nowrap" class="ft914">38.3%&#160;</p>
<p style="position:absolute;top:177px;left:309px;white-space:nowrap" class="ft914">(35.6-41.1)&#160;</p>
<p style="position:absolute;top:160px;left:447px;white-space:nowrap" class="ft914">35.6%&#160;</p>
<p style="position:absolute;top:177px;left:433px;white-space:nowrap" class="ft914">(31.9-39.5)&#160;</p>
<p style="position:absolute;top:169px;left:599px;white-space:nowrap" class="ft914">-&#160;</p>
<p style="position:absolute;top:160px;left:713px;white-space:nowrap" class="ft914">-2.7%&#160;</p>
<p style="position:absolute;top:177px;left:702px;white-space:nowrap" class="ft914">(-7.2-<b>1.9</b>)&#160;</p>
<p style="position:absolute;top:225px;left:134px;white-space:nowrap" class="ft926"><b>B1</b></p>
<p style="position:absolute;top:208px;left:134px;white-space:nowrap" class="ft926"><b>&#160;</b></p>
<p style="position:absolute;top:195px;left:198px;white-space:nowrap" class="ft914">GMT&#160;</p>
<p style="position:absolute;top:213px;left:186px;white-space:nowrap" class="ft914">(95% CI)&#160;</p>
<p style="position:absolute;top:195px;left:326px;white-space:nowrap" class="ft914">133.2&#160;</p>
<p style="position:absolute;top:213px;left:301px;white-space:nowrap" class="ft914">(125.3-141.7)&#160;</p>
<p style="position:absolute;top:195px;left:450px;white-space:nowrap" class="ft914">115.6&#160;</p>
<p style="position:absolute;top:213px;left:426px;white-space:nowrap" class="ft914">(106.4-125.6)&#160;</p>
<p style="position:absolute;top:195px;left:592px;white-space:nowrap" class="ft914">0.9&#160;</p>
<p style="position:absolute;top:213px;left:575px;white-space:nowrap" class="ft914">(0.8-<b>1.0</b>)&#160;</p>
<p style="position:absolute;top:204px;left:728px;white-space:nowrap" class="ft914">-&#160;</p>
<p style="position:absolute;top:231px;left:168px;white-space:nowrap" class="ft914">Seroconversion&#160;</p>
<p style="position:absolute;top:248px;left:168px;white-space:nowrap" class="ft914">Rateb&#160;(95% CI)&#160;</p>
<p style="position:absolute;top:231px;left:323px;white-space:nowrap" class="ft914">36.6%&#160;</p>
<p style="position:absolute;top:248px;left:309px;white-space:nowrap" class="ft914">(33.9-39.3)&#160;</p>
<p style="position:absolute;top:231px;left:447px;white-space:nowrap" class="ft914">34.8%&#160;</p>
<p style="position:absolute;top:248px;left:433px;white-space:nowrap" class="ft914">(31.1-38.7)&#160;</p>
<p style="position:absolute;top:239px;left:599px;white-space:nowrap" class="ft914">-&#160;</p>
<p style="position:absolute;top:231px;left:713px;white-space:nowrap" class="ft914">-1.8%&#160;</p>
<p style="position:absolute;top:248px;left:702px;white-space:nowrap" class="ft914">(-6.2-<b>2.8</b>)&#160;</p>
<p style="position:absolute;top:295px;left:134px;white-space:nowrap" class="ft926"><b>B2</b></p>
<p style="position:absolute;top:278px;left:134px;white-space:nowrap" class="ft926"><b>&#160;</b></p>
<p style="position:absolute;top:266px;left:198px;white-space:nowrap" class="ft914">GMT&#160;</p>
<p style="position:absolute;top:283px;left:186px;white-space:nowrap" class="ft914">(95% CI)&#160;</p>
<p style="position:absolute;top:266px;left:326px;white-space:nowrap" class="ft914">177.2&#160;</p>
<p style="position:absolute;top:283px;left:301px;white-space:nowrap" class="ft914">(167.6-187.5)&#160;</p>
<p style="position:absolute;top:266px;left:450px;white-space:nowrap" class="ft914">164.0&#160;</p>
<p style="position:absolute;top:283px;left:426px;white-space:nowrap" class="ft914">(151.4-177.7)&#160;</p>
<p style="position:absolute;top:266px;left:592px;white-space:nowrap" class="ft914">0.9&#160;</p>
<p style="position:absolute;top:283px;left:575px;white-space:nowrap" class="ft914">(0.9-<b>1.0</b>)&#160;</p>
<p style="position:absolute;top:274px;left:728px;white-space:nowrap" class="ft914">-&#160;</p>
<p style="position:absolute;top:301px;left:168px;white-space:nowrap" class="ft914">Seroconversion&#160;</p>
<p style="position:absolute;top:318px;left:168px;white-space:nowrap" class="ft914">Rateb&#160;(95% CI)&#160;</p>
<p style="position:absolute;top:301px;left:323px;white-space:nowrap" class="ft914">39.8%&#160;</p>
<p style="position:absolute;top:318px;left:309px;white-space:nowrap" class="ft914">(37.0-42.5)&#160;</p>
<p style="position:absolute;top:301px;left:447px;white-space:nowrap" class="ft914">35.4%&#160;</p>
<p style="position:absolute;top:318px;left:433px;white-space:nowrap" class="ft914">(31.7-39.2)&#160;</p>
<p style="position:absolute;top:310px;left:599px;white-space:nowrap" class="ft914">-&#160;</p>
<p style="position:absolute;top:301px;left:713px;white-space:nowrap" class="ft914">-4.4%&#160;</p>
<p style="position:absolute;top:318px;left:702px;white-space:nowrap" class="ft914">(-8.9-<b>0.2</b>)&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft96">Abbreviations: GMT&#160;=&#160;geometric&#160;mean&#160;titre;&#160;CI&#160;=&#160;confidence&#160;interval.&#160;&#160;<br/>a&#160;The&#160;comparator&#160;vaccine&#160;for&#160;noninferiority&#160;comparisons&#160;for&#160;A/H1N1,&#160;A/H3N2&#160;and&#160;B1&#160;is&#160;TIV1c,&#160;for&#160;B2&#160;it is&#160;<br/>TIV2c.&#160;<br/>b&#160;Seroconversion&#160;rate&#160;=&#160;percentage&#160;of&#160;subjects with&#160;either&#160;a&#160;pre-vaccination&#160;HI&#160;titre&#160;&lt;1:10&#160;and&#160;post-vaccination&#160;<br/>HI&#160;titre&#160;≥1:40&#160;or&#160;with&#160;a&#160;pre-vaccination&#160;HI&#160;titre&#160;≥1:10&#160;and&#160;a&#160;minimum&#160;4-fold&#160;increase&#160;in&#160;post-vaccination&#160;HI&#160;<br/>antibody&#160;titre.&#160;<br/><b>Bold</b>&#160;=&#160;Non-inferiority&#160;criterion&#160;met.&#160;<br/>&#160;<br/><i>Clinical&#160;efficacy of&#160;cell-based&#160;trivalent&#160;influenza vaccine (TIVc)&#160;against&#160;culture-confirmed&#160;influenza&#160;<br/>in adults&#160;<br/>&#160;<br/></i>The efficacy&#160;experience with TIVc is relevant&#160;to&#160;Flucelvax Tetra&#160;because&#160;both&#160;vaccines are&#160;<br/>manufactured using&#160;the same process&#160;and have overlapping&#160;compositions.&#160;&#160;<br/>&#160;<br/>A&#160;multinational,&#160;randomised, observer-blinded,&#160;placebo-controlled&#160;trial&#160;(V58P13)&#160;was&#160;performed to&#160;<br/>assess&#160;clinical&#160;efficacy&#160;and&#160;safety of&#160;TIVc during&#160;the&#160;2007-2008 influenza season&#160;in adults aged 18&#160;to&#160;<br/>less&#160;than 50&#160;years. A total&#160;of&#160;11,404&#160;subjects were&#160;enrolled to&#160;receive TIVc (N&#160;=&#160;3828), Agrippal&#160;<br/>(N&#160;=&#160;3676)&#160;or&#160;placebo (N&#160;=&#160;3900)&#160;in a&#160;1:1:1&#160;ratio.&#160;&#160;</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft96">TIVc efficacy was&#160;defined&#160;as&#160;the prevention of&#160;culture-confirmed symptomatic&#160;influenza&#160;illness&#160;<br/>caused by viruses&#160;antigenically matched&#160;to those&#160;in&#160;the&#160;vaccine&#160;compared to placebo. Influenza&#160;cases&#160;<br/>were&#160;identified by active&#160;and passive&#160;surveillance of&#160;influenza-like&#160;illness&#160;(ILI). ILI&#160;was&#160;defined&#160;<br/>according to Centers&#160;for&#160;Disease Control&#160;and Prevention (CDC)&#160;case definition,&#160;i.e., a&#160;fever&#160;(oral&#160;<br/>temperature&#160;<b>≥</b>100.0°F / 38°C)&#160;and cough or&#160;sore&#160;throat. After&#160;an&#160;episode&#160;of&#160;ILI, nose&#160;and throat&#160;swab&#160;<br/>samples were collected for&#160;analysis. Vaccine efficacies&#160;against&#160;vaccine-matched influenza&#160;viral&#160;<br/>strains, against&#160;all&#160;influenza&#160;viral&#160;strains, and against&#160;individual&#160;influenza viral&#160;subtypes&#160;were&#160;<br/>calculated&#160;(Table&#160;4).&#160;<br/>&#160;<br/><b>Table&#160;4:&#160;&#160;&#160;Comparative&#160;efficacy&#160;of&#160;TIVc&#160;versus&#160;placebo&#160;against&#160;culture-confirmed&#160;influenza&#160;by&#160;</b></p>
<p style="position:absolute;top:865px;left:183px;white-space:nowrap" class="ft91"><b>influenza&#160;viral&#160;subtype&#160;(V58P13)&#160;</b></p>
<p style="position:absolute;top:889px;left:182px;white-space:nowrap" class="ft913"><b>&#160;</b></p>
<p style="position:absolute;top:889px;left:341px;white-space:nowrap" class="ft913"><b>TIVc&#160;</b></p>
<p style="position:absolute;top:906px;left:324px;white-space:nowrap" class="ft913"><b>(N&#160;=&#160;3776)&#160;</b></p>
<p style="position:absolute;top:889px;left:532px;white-space:nowrap" class="ft913"><b>Placebo&#160;</b></p>
<p style="position:absolute;top:906px;left:523px;white-space:nowrap" class="ft913"><b>(N&#160;=&#160;3843)&#160;</b></p>
<p style="position:absolute;top:889px;left:678px;white-space:nowrap" class="ft913"><b>Vaccine Efficacy*&#160;</b></p>
<p style="position:absolute;top:932px;left:182px;white-space:nowrap" class="ft913"><b>&#160;</b></p>
<p style="position:absolute;top:932px;left:268px;white-space:nowrap" class="ft913"><b>Attack&#160;Rate&#160;</b></p>
<p style="position:absolute;top:950px;left:294px;white-space:nowrap" class="ft913"><b>(%)&#160;</b></p>
<p style="position:absolute;top:932px;left:371px;white-space:nowrap" class="ft913"><b>Number&#160;of&#160;</b></p>
<p style="position:absolute;top:950px;left:363px;white-space:nowrap" class="ft913"><b>Subjects&#160;with&#160;</b></p>
<p style="position:absolute;top:967px;left:376px;white-space:nowrap" class="ft913"><b>Influenza&#160;</b></p>
<p style="position:absolute;top:932px;left:467px;white-space:nowrap" class="ft913"><b>Attack&#160;Rate&#160;</b></p>
<p style="position:absolute;top:950px;left:493px;white-space:nowrap" class="ft913"><b>(%)&#160;</b></p>
<p style="position:absolute;top:932px;left:570px;white-space:nowrap" class="ft913"><b>Number&#160;of&#160;</b></p>
<p style="position:absolute;top:950px;left:562px;white-space:nowrap" class="ft913"><b>Subjects&#160;with&#160;</b></p>
<p style="position:absolute;top:967px;left:575px;white-space:nowrap" class="ft913"><b>Influenza&#160;</b></p>
<p style="position:absolute;top:932px;left:680px;white-space:nowrap" class="ft913"><b>%&#160;</b></p>
<p style="position:absolute;top:932px;left:724px;white-space:nowrap" class="ft913"><b>Lower&#160;Limit&#160;</b></p>
<p style="position:absolute;top:950px;left:741px;white-space:nowrap" class="ft913"><b>of&#160;One-</b></p>
<p style="position:absolute;top:967px;left:724px;white-space:nowrap" class="ft913"><b>Sided&#160;97.5%&#160;</b></p>
<p style="position:absolute;top:984px;left:756px;white-space:nowrap" class="ft913"><b>CI&#160;</b></p>
<p style="position:absolute;top:1011px;left:111px;white-space:nowrap" class="ft913"><b>Antigenically&#160;Matched&#160;Strains&#160;</b></p>
<p style="position:absolute;top:1037px;left:111px;white-space:nowrap" class="ft913"><b>Overall&#160;</b></p>
<p style="position:absolute;top:1037px;left:293px;white-space:nowrap" class="ft913"><b>0.19&#160;</b></p>
<p style="position:absolute;top:1037px;left:402px;white-space:nowrap" class="ft913"><b>7&#160;</b></p>
<p style="position:absolute;top:1037px;left:492px;white-space:nowrap" class="ft913"><b>1.14&#160;</b></p>
<p style="position:absolute;top:1037px;left:598px;white-space:nowrap" class="ft913"><b>44&#160;</b></p>
<p style="position:absolute;top:1037px;left:674px;white-space:nowrap" class="ft913"><b>83.8&#160;</b></p>
<p style="position:absolute;top:1037px;left:752px;white-space:nowrap" class="ft913"><b>61.0&#160;</b></p>
<p style="position:absolute;top:1064px;left:111px;white-space:nowrap" class="ft919"><b>Individual&#160;<br/>strains&#160;</b></p>
<p style="position:absolute;top:1064px;left:189px;white-space:nowrap" class="ft913"><b>A/H3N2**&#160;</b></p>
<p style="position:absolute;top:1064px;left:293px;white-space:nowrap" class="ft914">0.05&#160;&#160;</p>
<p style="position:absolute;top:1064px;left:402px;white-space:nowrap" class="ft914">2&#160;</p>
<p style="position:absolute;top:1064px;left:502px;white-space:nowrap" class="ft914">0&#160;</p>
<p style="position:absolute;top:1064px;left:601px;white-space:nowrap" class="ft914">0&#160;</p>
<p style="position:absolute;top:1064px;left:683px;white-space:nowrap" class="ft914">--&#160;</p>
<p style="position:absolute;top:1064px;left:760px;white-space:nowrap" class="ft914">--&#160;</p>
<p style="position:absolute;top:1090px;left:189px;white-space:nowrap" class="ft913"><b>A/H1N1&#160;</b></p>
<p style="position:absolute;top:1090px;left:293px;white-space:nowrap" class="ft914">0.13&#160;</p>
<p style="position:absolute;top:1090px;left:402px;white-space:nowrap" class="ft914">5&#160;</p>
<p style="position:absolute;top:1090px;left:492px;white-space:nowrap" class="ft914">1.12&#160;</p>
<p style="position:absolute;top:1090px;left:598px;white-space:nowrap" class="ft914">43&#160;</p>
<p style="position:absolute;top:1090px;left:674px;white-space:nowrap" class="ft914">88.2<b>&#160;</b></p>
<p style="position:absolute;top:1090px;left:752px;white-space:nowrap" class="ft914">67.4&#160;</p>
<p style="position:absolute;top:1117px;left:189px;white-space:nowrap" class="ft913"><b>B**&#160;</b></p>
<p style="position:absolute;top:1117px;left:302px;white-space:nowrap" class="ft914">0&#160;</p>
<p style="position:absolute;top:1117px;left:402px;white-space:nowrap" class="ft914">0&#160;</p>
<p style="position:absolute;top:1117px;left:492px;white-space:nowrap" class="ft914">0.03&#160;</p>
<p style="position:absolute;top:1117px;left:601px;white-space:nowrap" class="ft914">1&#160;</p>
<p style="position:absolute;top:1117px;left:683px;white-space:nowrap" class="ft914">--&#160;</p>
<p style="position:absolute;top:1117px;left:760px;white-space:nowrap" class="ft914">--&#160;</p>
<p style="position:absolute;top:1144px;left:111px;white-space:nowrap" class="ft913"><b>All Culture-Confirmed&#160;Influenza&#160;</b></p>
</div>
<!-- Page 10 -->
<a name="10"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1029{font-size:17px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page10-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft103">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft100">10&#160;</p>
<p style="position:absolute;top:94px;left:111px;white-space:nowrap" class="ft1013"><b>Overall&#160;</b></p>
<p style="position:absolute;top:94px;left:293px;white-space:nowrap" class="ft1013"><b>1.11&#160;</b></p>
<p style="position:absolute;top:94px;left:398px;white-space:nowrap" class="ft1013"><b>42&#160;</b></p>
<p style="position:absolute;top:94px;left:492px;white-space:nowrap" class="ft1013"><b>3.64&#160;</b></p>
<p style="position:absolute;top:94px;left:594px;white-space:nowrap" class="ft1013"><b>140&#160;</b></p>
<p style="position:absolute;top:94px;left:674px;white-space:nowrap" class="ft1013"><b>69.5&#160;</b></p>
<p style="position:absolute;top:94px;left:752px;white-space:nowrap" class="ft1013"><b>55.0&#160;</b></p>
<p style="position:absolute;top:121px;left:111px;white-space:nowrap" class="ft1019"><b>Individual&#160;<br/>strains&#160;</b></p>
<p style="position:absolute;top:121px;left:189px;white-space:nowrap" class="ft1013"><b>A/H3N2&#160;</b></p>
<p style="position:absolute;top:121px;left:293px;white-space:nowrap" class="ft1014">0.16&#160;</p>
<p style="position:absolute;top:121px;left:402px;white-space:nowrap" class="ft1014">6&#160;</p>
<p style="position:absolute;top:121px;left:492px;white-space:nowrap" class="ft1014">0.65&#160;</p>
<p style="position:absolute;top:121px;left:598px;white-space:nowrap" class="ft1014">25&#160;</p>
<p style="position:absolute;top:121px;left:674px;white-space:nowrap" class="ft1014">75.6&#160;</p>
<p style="position:absolute;top:121px;left:752px;white-space:nowrap" class="ft1014">35.1&#160;</p>
<p style="position:absolute;top:147px;left:189px;white-space:nowrap" class="ft1013"><b>A/H1N1&#160;</b></p>
<p style="position:absolute;top:147px;left:293px;white-space:nowrap" class="ft1014">0.16&#160;</p>
<p style="position:absolute;top:147px;left:402px;white-space:nowrap" class="ft1014">6&#160;</p>
<p style="position:absolute;top:147px;left:492px;white-space:nowrap" class="ft1014">1.48&#160;</p>
<p style="position:absolute;top:147px;left:598px;white-space:nowrap" class="ft1014">57&#160;</p>
<p style="position:absolute;top:147px;left:674px;white-space:nowrap" class="ft1014">89.3&#160;</p>
<p style="position:absolute;top:147px;left:752px;white-space:nowrap" class="ft1014">73.0&#160;</p>
<p style="position:absolute;top:174px;left:189px;white-space:nowrap" class="ft1013"><b>B&#160;</b></p>
<p style="position:absolute;top:174px;left:293px;white-space:nowrap" class="ft1014">0.79&#160;</p>
<p style="position:absolute;top:174px;left:398px;white-space:nowrap" class="ft1014">30&#160;</p>
<p style="position:absolute;top:174px;left:492px;white-space:nowrap" class="ft1014">1.59&#160;</p>
<p style="position:absolute;top:174px;left:598px;white-space:nowrap" class="ft1014">61&#160;</p>
<p style="position:absolute;top:174px;left:674px;white-space:nowrap" class="ft1014">49.9&#160;</p>
<p style="position:absolute;top:174px;left:752px;white-space:nowrap" class="ft1014">18.2&#160;</p>
<p style="position:absolute;top:194px;left:117px;white-space:nowrap" class="ft109">*&#160;&#160;</p>
<p style="position:absolute;top:196px;left:138px;white-space:nowrap" class="ft1018">Simultaneous&#160;one-sided&#160;97.5% confidence&#160;intervals for&#160;the&#160;vaccine&#160;efficacy&#160;of&#160;each&#160;influenza&#160;vaccine&#160;<br/>relative&#160;to&#160;placebo&#160;based&#160;on&#160;the&#160;Sidak-corrected&#160;score&#160;confidence&#160;intervals for&#160;the&#160;two&#160;relative&#160;risks.&#160;&#160;<br/>Vaccine&#160;Efficacy&#160;=&#160;(1&#160;-&#160;Relative&#160;Risk)&#160;x&#160;100%;&#160;</p>
<p style="position:absolute;top:246px;left:117px;white-space:nowrap" class="ft109">**&#160;&#160;&#160;There&#160;were&#160;too&#160;few&#160;cases of&#160;influenza&#160;due&#160;to&#160;vaccine-matched&#160;influenza&#160;A/H3N2&#160;or&#160;B&#160;to&#160;adequately&#160;assess&#160;</p>
<p style="position:absolute;top:265px;left:138px;white-space:nowrap" class="ft1014">vaccine&#160;efficacy.&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft106">&#160;<br/>Paediatric&#160;population&#160;&#160;<br/>&#160;<br/><i>Immunogenicity&#160;of&#160;Flucelvax Tetra&#160;in Children and Adolescents&#160;4&#160;to&#160;less than 18&#160;Years of&#160;Age&#160;<br/></i>&#160;<br/>Immunogenicity of&#160;Flucelvax Tetra&#160;was evaluated in&#160;children&#160;4&#160;to&#160;less&#160;than&#160;18&#160;years of&#160;age&#160;as&#160;part&#160;of&#160;a&#160;<br/>randomised,&#160;double-blind,&#160;controlled&#160;study&#160;(V130_03). In this&#160;study, subjects received&#160;Flucelvax&#160;<br/>Tetra&#160;(N&#160;=&#160;1159)&#160;or&#160;one of&#160;the&#160;two formulations of&#160;comparator&#160;cell-based&#160;trivalent&#160;influenza vaccine&#160;<br/>(TIVc)&#160;[TIV1c (N&#160;=&#160;593),&#160;or&#160;TIV2c (N&#160;=&#160;580)].&#160;The&#160;immune&#160;response&#160;to&#160;each&#160;of&#160;the vaccine&#160;antigens&#160;<br/>was&#160;assessed 21&#160;days&#160;after&#160;vaccination.&#160;<br/>&#160;<br/>The immunogenicity endpoints were&#160;GMTs of&#160;HI&#160;antibodies&#160;response and percentage&#160;of&#160;subjects who&#160;<br/>achieved&#160;seroconversions&#160;(seroconversion&#160;rate),&#160;defined as&#160;a&#160;pre-vaccination HI&#160;titre of&#160;&lt;1:10 with a&#160;<br/>post-vaccination&#160;titre&#160;≥1:40&#160;or&#160;with a pre-vaccination&#160;HI&#160;titre ≥&#160;1:10 and&#160;a minimum&#160;4-fold&#160;increase in&#160;<br/>serum&#160;HI&#160;antibody titre.&#160;<br/>&#160;<br/>Flucelvax&#160;Tetra&#160;was noninferior&#160;to TIVc&#160;in&#160;children 4&#160;to less than 18&#160;years of&#160;age.&#160;Non-inferiority was&#160;<br/>established for&#160;all&#160;4 influenza&#160;strains&#160;included in the&#160;Flucelvax Tetra, as&#160;assessed&#160;by ratios of&#160;GMTs&#160;<br/>and the differences in&#160;the percentages&#160;of&#160;subjects achieving seroconversion&#160;at&#160;3 weeks&#160;following&#160;<br/>vaccination. The&#160;antibody&#160;response to influenza B strains contained&#160;in&#160;Flucelvax Tetra&#160;was&#160;superior&#160;to&#160;<br/>the antibody&#160;response after&#160;vaccination&#160;with TIVc containing an&#160;influenza&#160;B&#160;strain&#160;from&#160;the alternate&#160;<br/>lineage. There was no evidence&#160;that&#160;the addition&#160;of&#160;the&#160;second B&#160;strain resulted in&#160;immune&#160;<br/>interference&#160;to other&#160;strains&#160;included&#160;in&#160;the&#160;vaccine.&#160;<br/>&#160;<br/>The&#160;immunogenicity&#160;data&#160;in subjects&#160;4&#160;to&#160;less&#160;than 18&#160;years of&#160;age&#160;are&#160;summarised in Table&#160;5.&#160;<br/>&#160;<br/><b>Table&#160;5:&#160;&#160;&#160;GMTs&#160;and&#160;seroconversion rates (with 95% CI)&#160;in subjects&#160;4&#160;to &lt;18 years&#160;of&#160;age,&#160;</b></p>
<p style="position:absolute;top:795px;left:183px;white-space:nowrap" class="ft1029"><b>3&#160;weeks&#160;after&#160;vaccination&#160;with Flucelvax Tetra&#160;or TIV1c/TIV2c&#160;-&#160;Per&#160;Protocol&#160;Set&#160;<br/>(V130_03)&#160;</b></p>
<p style="position:absolute;top:846px;left:107px;white-space:nowrap" class="ft1013"><b>&#160;</b></p>
<p style="position:absolute;top:844px;left:245px;white-space:nowrap" class="ft1016"><b>&#160;</b></p>
<p style="position:absolute;top:846px;left:396px;white-space:nowrap" class="ft1013"><b>Flucelvax&#160;Tetra&#160;</b></p>
<p style="position:absolute;top:846px;left:614px;white-space:nowrap" class="ft1013"><b>TIV1c/TIV2ca</b>&#160;</p>
<p style="position:absolute;top:917px;left:133px;white-space:nowrap" class="ft1026"><b>A/H</b></p>
<p style="position:absolute;top:891px;left:133px;white-space:nowrap" class="ft1026"><b>1</b></p>
<p style="position:absolute;top:883px;left:133px;white-space:nowrap" class="ft1026"><b>N1</b></p>
<p style="position:absolute;top:865px;left:133px;white-space:nowrap" class="ft1026"><b>&#160;</b></p>
<p style="position:absolute;top:871px;left:245px;white-space:nowrap" class="ft1013"><b>&#160;</b></p>
<p style="position:absolute;top:871px;left:418px;white-space:nowrap" class="ft1014">N&#160;=&#160;1014&#160;</p>
<p style="position:absolute;top:871px;left:635px;white-space:nowrap" class="ft1014">N&#160;=&#160;510&#160;</p>
<p style="position:absolute;top:896px;left:194px;white-space:nowrap" class="ft1013"><b>GMT&#160;(95%&#160;CI)&#160;</b></p>
<p style="position:absolute;top:896px;left:392px;white-space:nowrap" class="ft1014">1090&#160;(1027-1157)&#160;</p>
<p style="position:absolute;top:896px;left:605px;white-space:nowrap" class="ft1014">1125&#160;(1034-1224)&#160;</p>
<p style="position:absolute;top:921px;left:176px;white-space:nowrap" class="ft1013"><b>Seroconversion Rateb&#160;</b></p>
<p style="position:absolute;top:921px;left:407px;white-space:nowrap" class="ft1013"><b>72%</b>&#160;(69-75)&#160;</p>
<p style="position:absolute;top:921px;left:621px;white-space:nowrap" class="ft1013"><b>75%</b>&#160;(70-78)&#160;</p>
<p style="position:absolute;top:993px;left:133px;white-space:nowrap" class="ft1026"><b>A/H</b></p>
<p style="position:absolute;top:966px;left:133px;white-space:nowrap" class="ft1026"><b>3</b></p>
<p style="position:absolute;top:959px;left:133px;white-space:nowrap" class="ft1026"><b>N2</b></p>
<p style="position:absolute;top:940px;left:133px;white-space:nowrap" class="ft1026"><b>&#160;</b></p>
<p style="position:absolute;top:947px;left:245px;white-space:nowrap" class="ft1013"><b>&#160;</b></p>
<p style="position:absolute;top:947px;left:418px;white-space:nowrap" class="ft1014">N&#160;=&#160;1013&#160;</p>
<p style="position:absolute;top:947px;left:635px;white-space:nowrap" class="ft1014">N&#160;=&#160;510&#160;</p>
<p style="position:absolute;top:972px;left:194px;white-space:nowrap" class="ft1013"><b>GMT&#160;(95%&#160;CI)&#160;</b></p>
<p style="position:absolute;top:972px;left:404px;white-space:nowrap" class="ft1014">738&#160;(703-774)&#160;</p>
<p style="position:absolute;top:972px;left:617px;white-space:nowrap" class="ft1014">776&#160;(725-831)&#160;</p>
<p style="position:absolute;top:997px;left:176px;white-space:nowrap" class="ft1013"><b>Seroconversion Rateb&#160;</b></p>
<p style="position:absolute;top:997px;left:407px;white-space:nowrap" class="ft1013"><b>47%</b>&#160;(44-50)&#160;</p>
<p style="position:absolute;top:997px;left:621px;white-space:nowrap" class="ft1013"><b>51%</b>&#160;(46-55)&#160;</p>
<p style="position:absolute;top:1051px;left:133px;white-space:nowrap" class="ft1026"><b>B1</b></p>
<p style="position:absolute;top:1033px;left:133px;white-space:nowrap" class="ft1026"><b>&#160;</b></p>
<p style="position:absolute;top:1022px;left:245px;white-space:nowrap" class="ft1013"><b>&#160;</b></p>
<p style="position:absolute;top:1022px;left:418px;white-space:nowrap" class="ft1014">N&#160;=&#160;1013&#160;</p>
<p style="position:absolute;top:1022px;left:635px;white-space:nowrap" class="ft1014">N&#160;=&#160;510&#160;</p>
<p style="position:absolute;top:1047px;left:194px;white-space:nowrap" class="ft1013"><b>GMT&#160;(95%&#160;CI)&#160;</b></p>
<p style="position:absolute;top:1047px;left:404px;white-space:nowrap" class="ft1014">155&#160;(146-165)&#160;</p>
<p style="position:absolute;top:1047px;left:617px;white-space:nowrap" class="ft1014">154&#160;(141-168)&#160;</p>
<p style="position:absolute;top:1073px;left:176px;white-space:nowrap" class="ft1013"><b>Seroconversion Rateb&#160;</b></p>
<p style="position:absolute;top:1073px;left:407px;white-space:nowrap" class="ft1013"><b>66%</b>&#160;(63-69)&#160;</p>
<p style="position:absolute;top:1073px;left:621px;white-space:nowrap" class="ft1013"><b>66%</b>&#160;(62-70)&#160;</p>
<p style="position:absolute;top:1126px;left:133px;white-space:nowrap" class="ft1026"><b>B2</b></p>
<p style="position:absolute;top:1109px;left:133px;white-space:nowrap" class="ft1026"><b>&#160;</b></p>
<p style="position:absolute;top:1098px;left:245px;white-space:nowrap" class="ft1013"><b>&#160;</b></p>
<p style="position:absolute;top:1098px;left:418px;white-space:nowrap" class="ft1014">N&#160;=&#160;1009&#160;</p>
<p style="position:absolute;top:1098px;left:635px;white-space:nowrap" class="ft1014">N&#160;=&#160;501&#160;</p>
<p style="position:absolute;top:1123px;left:194px;white-space:nowrap" class="ft1013"><b>GMT&#160;(95%&#160;CI)&#160;</b></p>
<p style="position:absolute;top:1123px;left:404px;white-space:nowrap" class="ft1014">185&#160;(171-200)&#160;</p>
<p style="position:absolute;top:1123px;left:617px;white-space:nowrap" class="ft1014">185&#160;(166-207)&#160;</p>
<p style="position:absolute;top:1148px;left:176px;white-space:nowrap" class="ft1013"><b>Seroconversion Rateb&#160;</b></p>
<p style="position:absolute;top:1148px;left:407px;white-space:nowrap" class="ft1013"><b>73%</b>&#160;(70-76)&#160;</p>
<p style="position:absolute;top:1148px;left:621px;white-space:nowrap" class="ft1013"><b>71%</b>&#160;(67-75)&#160;</p>
</div>
<!-- Page 11 -->
<a name="11"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1130{font-size:18px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft1131{font-size:10px;font-family:BCDEEE+TimesNewRomanPS;color:#000000;}
	.ft1132{font-size:9px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft1133{font-size:14px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page11-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft113">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft110">11&#160;</p>
<p style="position:absolute;top:87px;left:106px;white-space:nowrap" class="ft1118">a&#160;For&#160;H1N1,&#160;H3N2&#160;and&#160;B1&#160;influenza&#160;strains&#160;TIV1c&#160;data&#160;are&#160;presented,&#160;whereas&#160;for&#160;B2&#160;influenza&#160;strain&#160;TIV2c&#160;<br/>data&#160;are&#160;presented.&#160;<br/>b&#160;Seroconversion&#160;rate&#160;=&#160;percentage&#160;of&#160;subjects with&#160;either&#160;a&#160;pre-vaccination&#160;HI&#160;titre&#160;&lt;1:10&#160;and&#160;post-vaccination&#160;<br/>HI&#160;titre&#160;≥1:40&#160;or&#160;with&#160;a&#160;pre-vaccination&#160;HI&#160;titre&#160;≥1:10&#160;and&#160;a&#160;minimum&#160;4-fold&#160;increase&#160;in&#160;post-vaccination&#160;HI&#160;<br/>antibody&#160;titre.&#160;<br/><b>Bold</b>-&#160;CHMP immunogenicity&#160;criteria&#160;met.&#160;The&#160;percentage&#160;of&#160;subjects with&#160;seroconversion&#160;or&#160;significant&#160;<br/>increase&#160;in&#160;HI&#160;antibody&#160;titre&#160;is&#160;&gt;40%,&#160;the&#160;percentage&#160;of&#160;subjects&#160;achieving&#160;an&#160;HI&#160;titre&#160;≥1:40&#160;is&#160;&gt;70%.</p>
<p style="position:absolute;top:190px;left:715px;white-space:nowrap" class="ft1130">&#160;</p>
<p style="position:absolute;top:210px;left:106px;white-space:nowrap" class="ft115">&#160;<br/>&#160;<br/><i>Clinical&#160;efficacy of&#160;Flucelvax Tetra&#160;in the paediatric population 2 to&#160;less&#160;than&#160;18&#160;years&#160;of&#160;age&#160;<br/></i>&#160;<br/>Absolute efficacy of&#160;Flucelvax Tetra&#160;was&#160;evaluated in&#160;children 2 to less&#160;than&#160;18 years&#160;of&#160;age&#160;in Study&#160;<br/>V130_12.&#160;This was&#160;a&#160;multinational, randomised, non-influenza&#160;vaccine comparator-controlled&#160;<br/>efficacy study&#160;conducted in&#160;8 countries&#160;over&#160;3 influenza seasons,&#160;in which&#160;4514&#160;subjects&#160;were&#160;enrolled&#160;<br/>to&#160;received&#160;0.5&#160;ml&#160;of&#160;Flucelvax Tetra&#160;or&#160;a&#160;non-influenza comparator&#160;in a 1:1&#160;ratio.&#160;Based on&#160;influenza&#160;<br/>vaccination&#160;history, participants&#160;received one or&#160;two doses&#160;(28 days&#160;apart)&#160;of&#160;the&#160;study vaccine.&#160;&#160;</p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft112">Flucelvax&#160;Tetra</p>
<p style="position:absolute;top:393px;left:211px;white-space:nowrap" class="ft1130">&#160;efficacy&#160;was&#160;assessed&#160;by&#160;the&#160;prevention&#160;of&#160;confirmed&#160;influenza&#160;illness&#160;caused&#160;by&#160;any&#160;</p>
<p style="position:absolute;top:413px;left:106px;white-space:nowrap" class="ft116">influenza&#160;Type&#160;A&#160;or&#160;B&#160;strain.&#160;&#160;Influenza&#160;cases&#160;were&#160;identified&#160;by&#160;active&#160;surveillance&#160;of&#160;influenza-like&#160;<br/>illness&#160;(ILI)&#160;and&#160;confirmed&#160;by&#160;viral&#160;culture&#160;and/or&#160;real-time&#160;polymerase&#160;chain&#160;reaction&#160;(RT-PCR).&#160;&#160;An&#160;<br/>ILI&#160;episode&#160;was&#160;defined&#160;as&#160;a&#160;fever&#160;body&#160;temperature&#160;≥&#160;37.8°C)&#160;along&#160;with&#160;at&#160;least&#160;one&#160;of&#160;the&#160;following:&#160;<br/>cough,&#160;&#160;sore&#160;&#160;throat,&#160;&#160;nasal&#160;&#160;congestion,&#160;&#160;or&#160;&#160;rhinorrhoea.&#160;&#160;Vaccine&#160;&#160;efficacy&#160;&#160;against&#160;&#160;laboratory&#160;&#160;confirmed&#160;<br/>influenza&#160;was&#160;calculated&#160;(Table&#160;6).&#160;</p>
<p style="position:absolute;top:517px;left:106px;white-space:nowrap" class="ft116">&#160;<br/><b>Table&#160;6:&#160;Number of&#160;Subjects&#160;with First-Occurrence&#160;RT-PCR&#160;Confirmed or Culture Confirmed&#160;</b></p>
<p style="position:absolute;top:555px;left:183px;white-space:nowrap" class="ft1129"><b>Influenza and&#160;Absolute&#160;Vaccine Efficacy&#160;(95% CI),&#160;in Subjects 2 to less&#160;than&#160;18 Years&#160;<br/>of&#160;Age–&#160;FAS Efficacy1&#160;(Study V130_12)&#160;</b></p>
<p style="position:absolute;top:638px;left:115px;white-space:nowrap" class="ft1113"><b>&#160;</b></p>
<p style="position:absolute;top:602px;left:303px;white-space:nowrap" class="ft1113"><b>Number&#160;</b></p>
<p style="position:absolute;top:624px;left:296px;white-space:nowrap" class="ft1113"><b>of&#160;subjects&#160;</b></p>
<p style="position:absolute;top:645px;left:319px;white-space:nowrap" class="ft1113"><b>per&#160;</b></p>
<p style="position:absolute;top:667px;left:301px;white-space:nowrap" class="ft1113"><b>protocol1&#160;</b></p>
<p style="position:absolute;top:613px;left:388px;white-space:nowrap" class="ft1113"><b>Number&#160;</b></p>
<p style="position:absolute;top:634px;left:382px;white-space:nowrap" class="ft1113"><b>of&#160;cases of&#160;</b></p>
<p style="position:absolute;top:656px;left:385px;white-space:nowrap" class="ft1113"><b>influenza&#160;</b></p>
<p style="position:absolute;top:611px;left:473px;white-space:nowrap" class="ft1113"><b>Attack&#160;</b></p>
<p style="position:absolute;top:633px;left:479px;white-space:nowrap" class="ft1113"><b>Rate&#160;</b></p>
<p style="position:absolute;top:657px;left:482px;white-space:nowrap" class="ft1113"><b>(%)&#160;</b></p>
<p style="position:absolute;top:602px;left:574px;white-space:nowrap" class="ft1113"><b>Vaccine Efficacy&#160;(VE)&#160;&#160;</b></p>
<p style="position:absolute;top:649px;left:572px;white-space:nowrap" class="ft1113"><b>%&#160;</b></p>
<p style="position:absolute;top:649px;left:646px;white-space:nowrap" class="ft1113"><b>95%&#160;CI of&#160;VE&#160;</b></p>
<p style="position:absolute;top:698px;left:115px;white-space:nowrap" class="ft1113"><b>RT-PCR&#160;or&#160;Culture&#160;Confirmed&#160;Influenza</b>&#160;</p>
<p style="position:absolute;top:727px;left:115px;white-space:nowrap" class="ft112">Flucelvax&#160;Tetra&#160;</p>
<p style="position:absolute;top:728px;left:315px;white-space:nowrap" class="ft1114">2257&#160;</p>
<p style="position:absolute;top:728px;left:403px;white-space:nowrap" class="ft1114">175&#160;</p>
<p style="position:absolute;top:728px;left:485px;white-space:nowrap" class="ft1114">7.8&#160;</p>
<p style="position:absolute;top:728px;left:563px;white-space:nowrap" class="ft1114">54.63&#160;</p>
<p style="position:absolute;top:728px;left:654px;white-space:nowrap" class="ft1114">45.67,&#160;62.12&#160;</p>
<p style="position:absolute;top:757px;left:115px;white-space:nowrap" class="ft1114">Non-Influenza&#160;Comparator&#160;</p>
<p style="position:absolute;top:757px;left:315px;white-space:nowrap" class="ft1114">2252&#160;</p>
<p style="position:absolute;top:757px;left:403px;white-space:nowrap" class="ft1114">364&#160;</p>
<p style="position:absolute;top:757px;left:481px;white-space:nowrap" class="ft1114">16.2&#160;</p>
<p style="position:absolute;top:757px;left:577px;white-space:nowrap" class="ft1114">-&#160;</p>
<p style="position:absolute;top:757px;left:689px;white-space:nowrap" class="ft1114">-&#160;</p>
<p style="position:absolute;top:785px;left:115px;white-space:nowrap" class="ft1113"><b>Culture&#160;Confirmed&#160;Influenza</b>&#160;</p>
<p style="position:absolute;top:814px;left:115px;white-space:nowrap" class="ft112">Flucelvax&#160;Tetra&#160;</p>
<p style="position:absolute;top:815px;left:315px;white-space:nowrap" class="ft1114">2257&#160;</p>
<p style="position:absolute;top:815px;left:403px;white-space:nowrap" class="ft1114">115&#160;</p>
<p style="position:absolute;top:815px;left:485px;white-space:nowrap" class="ft1114">5.1&#160;</p>
<p style="position:absolute;top:815px;left:563px;white-space:nowrap" class="ft1114">60.81&#160;</p>
<p style="position:absolute;top:815px;left:654px;white-space:nowrap" class="ft1114">51.30,&#160;68.46&#160;</p>
<p style="position:absolute;top:844px;left:115px;white-space:nowrap" class="ft1114">Non-Influenza&#160;Comparator&#160;</p>
<p style="position:absolute;top:844px;left:315px;white-space:nowrap" class="ft1114">2252&#160;</p>
<p style="position:absolute;top:844px;left:403px;white-space:nowrap" class="ft1114">279&#160;</p>
<p style="position:absolute;top:844px;left:481px;white-space:nowrap" class="ft1114">12.4&#160;</p>
<p style="position:absolute;top:844px;left:577px;white-space:nowrap" class="ft1114">-&#160;</p>
<p style="position:absolute;top:844px;left:689px;white-space:nowrap" class="ft1114">-&#160;</p>
<p style="position:absolute;top:872px;left:115px;white-space:nowrap" class="ft1113"><b>Antigenically&#160;Matched&#160;Culture-Confirmed&#160;Influenza</b>&#160;</p>
<p style="position:absolute;top:901px;left:115px;white-space:nowrap" class="ft112">Flucelvax&#160;Tetra&#160;</p>
<p style="position:absolute;top:902px;left:315px;white-space:nowrap" class="ft1114">2257&#160;</p>
<p style="position:absolute;top:902px;left:407px;white-space:nowrap" class="ft1114">90&#160;</p>
<p style="position:absolute;top:902px;left:485px;white-space:nowrap" class="ft1114">4.0&#160;</p>
<p style="position:absolute;top:902px;left:563px;white-space:nowrap" class="ft1114">63.64&#160;</p>
<p style="position:absolute;top:902px;left:654px;white-space:nowrap" class="ft1114">53.64,&#160;71.48&#160;</p>
<p style="position:absolute;top:931px;left:115px;white-space:nowrap" class="ft1114">Non-Influenza&#160;Comparator&#160;</p>
<p style="position:absolute;top:931px;left:315px;white-space:nowrap" class="ft1114">2252&#160;</p>
<p style="position:absolute;top:931px;left:403px;white-space:nowrap" class="ft1114">236&#160;</p>
<p style="position:absolute;top:931px;left:481px;white-space:nowrap" class="ft1114">10.5&#160;</p>
<p style="position:absolute;top:931px;left:577px;white-space:nowrap" class="ft1114">-&#160;</p>
<p style="position:absolute;top:931px;left:689px;white-space:nowrap" class="ft1114">-&#160;</p>
<p style="position:absolute;top:958px;left:115px;white-space:nowrap" class="ft1132">1Number&#160;of&#160;subjects in&#160;the&#160;Full-Analysis Set&#160;(FAS)–&#160;Efficacy,&#160;which&#160;included&#160;all&#160;subjects randomised,&#160;received&#160;a&#160;</p>
<p style="position:absolute;top:978px;left:115px;white-space:nowrap" class="ft1133">study&#160;vaccination&#160;and&#160;provided&#160;efficacy&#160;data.&#160;</p>
<p style="position:absolute;top:1011px;left:106px;white-space:nowrap" class="ft115">&#160;<br/>&#160;<br/><b>5.2&#160;</b></p>
<p style="position:absolute;top:1049px;left:149px;white-space:nowrap" class="ft111"><b>Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:1068px;left:106px;white-space:nowrap" class="ft115">&#160;<br/>Not&#160;applicable.&#160;<br/>&#160;<br/><b>5.3&#160;</b></p>
<p style="position:absolute;top:1126px;left:149px;white-space:nowrap" class="ft111"><b>Preclinical&#160;safety data</b>&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft112">&#160;</p>
</div>
<!-- Page 12 -->
<a name="12"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page12-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft123">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft120">12&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft126">Non-clinical&#160;data&#160;reveal&#160;no&#160;special&#160;hazard&#160;for&#160;humans&#160;based&#160;on&#160;conventional&#160;studies&#160;of&#160;repeated dose&#160;<br/>toxicity&#160;and toxicity to&#160;reproduction&#160;and development.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:165px;left:149px;white-space:nowrap" class="ft121"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft126">&#160;<br/><b>6.1&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft121"><b>List&#160;of&#160;excipients</b>&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft125"><i>&#160;<br/></i>Sodium&#160;chloride&#160;<br/>Potassium&#160;chloride&#160;<br/>Magnesium&#160;chloride hexahydrate&#160;<br/>Disodium&#160;phosphate dihydrate&#160;<br/>Potassium&#160;dihydrogen phosphate&#160;<br/>Water&#160;for&#160;injections&#160;<br/>&#160;<br/><b>6.2&#160;</b></p>
<p style="position:absolute;top:374px;left:149px;white-space:nowrap" class="ft121"><b>Incompatibilities</b>&#160;</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft125">&#160;<br/>In the absence of&#160;compatibility studies,&#160;this&#160;medicinal&#160;product&#160;must&#160;not&#160;be&#160;mixed&#160;with other&#160;medicinal&#160;<br/>products.&#160;&#160;<br/>&#160;<br/><b>6.3&#160;</b></p>
<p style="position:absolute;top:469px;left:149px;white-space:nowrap" class="ft121"><b>Shelf&#160;life</b>&#160;</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft126">&#160;<br/>12 months&#160;<br/>&#160;<br/><b>6.4&#160;</b></p>
<p style="position:absolute;top:544px;left:149px;white-space:nowrap" class="ft121"><b>Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft126">&#160;<br/>Store&#160;in&#160;a refrigerator&#160;(2°C&#160;–&#160;8°C).&#160;<br/>Do not&#160;freeze.&#160;<br/>Keep the pre-filled syringe&#160;in the outer&#160;carton in&#160;order&#160;to protect&#160;from&#160;light.&#160;<br/>&#160;<br/><b>6.5&#160;</b></p>
<p style="position:absolute;top:660px;left:149px;white-space:nowrap" class="ft121"><b>Nature and&#160;contents of&#160;container&#160;&#160;</b></p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft126">&#160;<br/>0.5&#160;ml&#160;suspension&#160;in pre-filled syringes (type I&#160;glass),&#160;with a&#160;plunger&#160;stopper&#160;(bromobutyl&#160;rubber),&#160;<br/>with or&#160;without&#160;needle.&#160;&#160;<br/>&#160;<br/>Pack of&#160;1&#160;pre-filled syringe,&#160;with&#160;or&#160;without&#160;needle&#160;<br/>Pack&#160;of&#160;10 pre-filled syringes,&#160;with or&#160;without&#160;needles.&#160;<br/>&#160;<br/>Not&#160;all&#160;pack sizes&#160;may be&#160;marketed.&#160;<br/>&#160;<br/><b>6.6&#160;</b></p>
<p style="position:absolute;top:852px;left:149px;white-space:nowrap" class="ft121"><b>Special&#160;precautions for disposal&#160;and&#160;other handling</b>&#160;</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft125">&#160;<br/>Shake before use.&#160;After&#160;shaking,&#160;the normal&#160;appearance of&#160;the vaccine&#160;is&#160;a&#160;clear&#160;to&#160;slightly opalescent&#160;<br/>suspension.&#160;<br/>&#160;<br/>The vaccine should be visually inspected&#160;for&#160;particulate matter&#160;and discoloration&#160;prior&#160;to&#160;<br/>administration.&#160;In the&#160;event&#160;of&#160;any&#160;foreign particulate&#160;matter&#160;and/or&#160;variation of&#160;physical&#160;aspect&#160;is&#160;<br/>observed, do not&#160;administer&#160;the&#160;vaccine.&#160;<br/>&#160;<br/>Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be disposed of&#160;in&#160;accordance&#160;with local&#160;<br/>requirements.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:1099px;left:149px;white-space:nowrap" class="ft121"><b>MARKETING AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:1117px;left:106px;white-space:nowrap" class="ft122">&#160;</p>
</div>
<!-- Page 13 -->
<a name="13"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page13-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft133">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft130">13&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft136">Seqirus Netherlands B.V.&#160;<br/>Paasheuvelweg 28&#160;<br/>1105BJ Amsterdam&#160;<br/>Netherlands&#160;<br/>&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft131"><b>MARKETING AUTHORISATION&#160;NUMBER(S)&#160;&#160;</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft136">&#160;<br/>EU/1/18/1326/001&#160;<br/>EU/1/18/1326/002&#160;<br/>EU/1/18/1326/003&#160;<br/>EU/1/18/1326/004&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:355px;left:149px;white-space:nowrap" class="ft131"><b>DATE&#160;OF FIRST&#160;AUTHORISATION/RENEWAL&#160;OF THE&#160;AUTHORISATION</b>&#160;</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft135"><i>&#160;<br/></i>Date of&#160;first&#160;authorisation:&#160;12 December&#160;2018&#160;<br/>&#160;<br/><b>10.&#160;</b></p>
<p style="position:absolute;top:431px;left:149px;white-space:nowrap" class="ft131"><b>DATE&#160;OF REVISION&#160;OF THE&#160;TEXT&#160;</b></p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft135">&#160;<br/>&#160;<br/>Detailed&#160;information on&#160;this medicinal&#160;product&#160;is available&#160;on the website of&#160;the European Medicines&#160;<br/>Agenc<a href="http://www.ema.europa.eu/">y&#160;http://www.ema.europa.eu.</a>&#160;<br/>&#160;</p>
<p style="position:absolute;top:526px;left:322px;white-space:nowrap" class="ft132">&#160;</p>
</div>
<!-- Page 14 -->
<a name="14"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page14-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft143">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft140">14&#160;</p>
<p style="position:absolute;top:89px;left:116px;white-space:nowrap" class="ft146">&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:526px;left:409px;white-space:nowrap" class="ft141"><b>ANNEX&#160;II&#160;</b></p>
<p style="position:absolute;top:544px;left:447px;white-space:nowrap" class="ft141"><b>&#160;</b></p>
<p style="position:absolute;top:564px;left:181px;white-space:nowrap" class="ft141"><b>A.&#160;</b></p>
<p style="position:absolute;top:564px;left:234px;white-space:nowrap" class="ft1421"><b>MANUFACTURER(S) OF THE&#160;BIOLOGICAL&#160;ACTIVE&#160;SUBSTANCE(S)&#160;<br/>AND&#160;MANUFACTURER(S) RESPONSIBLE&#160;FOR&#160;BATCH&#160;RELEASE&#160;</b></p>
<p style="position:absolute;top:601px;left:181px;white-space:nowrap" class="ft1421"><b>&#160;<br/>B.&#160;</b></p>
<p style="position:absolute;top:620px;left:234px;white-space:nowrap" class="ft141"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS REGARDING&#160;SUPPLY&#160;AND&#160;USE&#160;</b></p>
<p style="position:absolute;top:639px;left:181px;white-space:nowrap" class="ft1429"><b>&#160;<br/>C.&#160;</b></p>
<p style="position:absolute;top:658px;left:234px;white-space:nowrap" class="ft1421"><b>OTHER&#160;CONDITIONS&#160;AND&#160;REQUIREMENTS OF THE&#160;MARKETING&#160;<br/>AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:696px;left:181px;white-space:nowrap" class="ft1421"><b>&#160;<br/>D.&#160;</b></p>
<p style="position:absolute;top:715px;left:234px;white-space:nowrap" class="ft1421"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS WITH&#160;REGARD&#160;TO&#160;THE&#160;SAFE&#160;AND&#160;<br/>EFFECTIVE&#160;USE&#160;OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:753px;left:181px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:772px;left:116px;white-space:nowrap" class="ft142">&#160;</p>
</div>
<!-- Page 15 -->
<a name="15"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1534{font-size:17px;font-family:TimesNewRomanPS;color:#339966;}
	.ft1535{font-size:17px;font-family:SymbolMT;color:#000000;}
	.ft1536{font-size:17px;font-family:ArialMT;color:#000000;}
	.ft1537{font-size:17px;line-height:18px;font-family:TimesNewRomanPS;color:#339966;}
-->
</style>
<div id="page15-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft153">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft150">15&#160;</p>
<p style="position:absolute;top:89px;left:116px;white-space:nowrap" class="ft151"><b>A.&#160;</b></p>
<p style="position:absolute;top:89px;left:160px;white-space:nowrap" class="ft1529"><b>MANUFACTURER(S) OF THE&#160;BIOLOGICAL&#160;ACTIVE&#160;SUBSTANCE(S)&#160;AND&#160;<br/>MANUFACTURER(S) RESPONSIBLE&#160;FOR BATCH&#160;RELEASE&#160;</b></p>
<p style="position:absolute;top:127px;left:116px;white-space:nowrap" class="ft155">&#160;<br/>Name&#160;and address&#160;of&#160;the&#160;manufacturer(s)&#160;of&#160;the biological&#160;active&#160;substance(s)&#160;<i>&#160;<br/></i>Seqirus Inc.&#160;<br/>475 Green Oaks&#160;Parkway&#160;<br/>Holly Springs&#160;<br/>NC&#160;27540&#160;<br/>United&#160;States&#160;<br/>&#160;<br/>Name&#160;and address&#160;of&#160;the&#160;manufacturer(s)&#160;responsible&#160;for&#160;batch&#160;release&#160;</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft155">&#160;&#160;Seqirus Netherlands&#160;B.V.&#160;<br/>&#160;&#160;Paasheuvelweg 28&#160;<br/>&#160;&#160;1105BJ Amsterdam&#160;</p>
<p style="position:absolute;top:355px;left:116px;white-space:nowrap" class="ft155">Netherlands&#160;<br/>&#160;</p>
<p style="position:absolute;top:393px;left:117px;white-space:nowrap" class="ft152">&#160;</p>
<p style="position:absolute;top:412px;left:116px;white-space:nowrap" class="ft155">&#160;<br/><b>B.&#160;</b></p>
<p style="position:absolute;top:431px;left:160px;white-space:nowrap" class="ft151"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS REGARDING&#160;SUPPLY&#160;AND&#160;USE&#160;</b></p>
<p style="position:absolute;top:450px;left:116px;white-space:nowrap" class="ft156">&#160;<br/>Medicinal&#160;product&#160;subject&#160;to medical&#160;prescription.&#160;<br/>&#160;</p>
<p style="position:absolute;top:502px;left:115px;white-space:nowrap" class="ft1535">•&#160;&#160;<b>Official&#160;batch release</b>&#160;</p>
<p style="position:absolute;top:527px;left:116px;white-space:nowrap" class="ft156">&#160;<br/>In accordance with Article&#160;114 of&#160;Directive 2001/83/EC, the official&#160;batch&#160;release&#160;will&#160;be&#160;<br/>undertaken by&#160;a state&#160;laboratory or&#160;a laboratory designated&#160;for&#160;that&#160;purpose.&#160;<br/>&#160;<br/>&#160;<br/><b>C.&#160;</b></p>
<p style="position:absolute;top:621px;left:160px;white-space:nowrap" class="ft1529"><b>OTHER&#160;CONDITIONS&#160;AND&#160;REQUIREMENTS OF THE&#160;MARKETING&#160;<br/>AUTHORISATION&#160;&#160;</b></p>
<p style="position:absolute;top:659px;left:116px;white-space:nowrap" class="ft152">&#160;</p>
<p style="position:absolute;top:674px;left:115px;white-space:nowrap" class="ft1535">•&#160;&#160;<b>Periodic&#160;safety update&#160;reports&#160;(PSURs)</b>&#160;</p>
<p style="position:absolute;top:699px;left:116px;white-space:nowrap" class="ft156">&#160;<br/>The requirements&#160;for&#160;submission of&#160;PSURs&#160;for&#160;this&#160;medicinal&#160;product&#160;are set&#160;out&#160;in the&#160;list&#160;of&#160;<br/>Union reference&#160;dates (EURD&#160;list)&#160;provided&#160;for&#160;under&#160;Article 107c(7)&#160;of&#160;Directive 2001/83/EC&#160;and&#160;<br/>any subsequent&#160;updates&#160;published on the European medicines&#160;web-portal.&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft152">&#160;</p>
<p style="position:absolute;top:794px;left:116px;white-space:nowrap" class="ft156">&#160;<br/><b>D.&#160;</b></p>
<p style="position:absolute;top:812px;left:160px;white-space:nowrap" class="ft1529"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS WITH&#160;REGARD&#160;TO&#160;THE&#160;SAFE&#160;AND&#160;<br/>EFFECTIVE&#160;USE&#160;OF THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:850px;left:116px;white-space:nowrap" class="ft152">&#160;</p>
<p style="position:absolute;top:865px;left:115px;white-space:nowrap" class="ft1535">•&#160;&#160;<b>Risk Management&#160;Plan&#160;(RMP)</b>&#160;</p>
<p style="position:absolute;top:890px;left:116px;white-space:nowrap" class="ft156">&#160;<br/>The&#160;marketing&#160;authorisation holder&#160;(MAH)&#160;&#160;shall&#160;perform&#160;the&#160;required pharmacovigilance&#160;activities&#160;<br/>and interventions detailed&#160;in the&#160;agreed RMP&#160;presented in&#160;Module 1.8.2 of&#160;the&#160;marketing&#160;<br/>authorisation&#160;and any agreed subsequent&#160;updates&#160;of&#160;the&#160;RMP.&#160;<br/>An updated RMP&#160;should be&#160;submitted:&#160;</p>
<p style="position:absolute;top:980px;left:142px;white-space:nowrap" class="ft1535">•&#160;&#160;At&#160;the&#160;request&#160;of&#160;the European Medicines&#160;Agency;&#160;</p>
<p style="position:absolute;top:1001px;left:142px;white-space:nowrap" class="ft1535">•&#160;&#160;Whenever&#160;the&#160;risk&#160;management&#160;system&#160;is&#160;modified,&#160;especially as the result&#160;of&#160;new&#160;</p>
<p style="position:absolute;top:1025px;left:169px;white-space:nowrap" class="ft156">information being received&#160;that&#160;may lead&#160;to a&#160;significant&#160;change&#160;to&#160;the benefit/risk&#160;profile or&#160;<br/>as&#160;the result&#160;of&#160;an&#160;important&#160;(pharmacovigilance or&#160;risk minimisation)&#160;milestone&#160;being&#160;<br/>reached.&#160;&#160;</p>
<p style="position:absolute;top:1082px;left:106px;white-space:nowrap" class="ft156">&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:1101px;left:322px;white-space:nowrap" class="ft152">&#160;</p>
</div>
<!-- Page 16 -->
<a name="16"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page16-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft163">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft160">16&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft165">&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:510px;left:447px;white-space:nowrap" class="ft161"><b>&#160;</b></p>
<p style="position:absolute;top:529px;left:406px;white-space:nowrap" class="ft161"><b>ANNEX&#160;III&#160;</b></p>
<p style="position:absolute;top:548px;left:447px;white-space:nowrap" class="ft161"><b>&#160;</b></p>
<p style="position:absolute;top:567px;left:294px;white-space:nowrap" class="ft161"><b>LABELLING AND&#160;PACKAGE&#160;LEAFLET&#160;</b></p>
<p style="position:absolute;top:586px;left:106px;white-space:nowrap" class="ft161"><b>&#160;</b></p>
<p style="position:absolute;top:586px;left:322px;white-space:nowrap" class="ft161"><b>&#160;</b></p>
</div>
<!-- Page 17 -->
<a name="17"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page17-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft173">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft170">17&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft175">&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:518px;left:447px;white-space:nowrap" class="ft171"><b>&#160;</b></p>
<p style="position:absolute;top:537px;left:387px;white-space:nowrap" class="ft171"><b>A. LABELLING&#160;</b></p>
<p style="position:absolute;top:556px;left:106px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:556px;left:322px;white-space:nowrap" class="ft172">&#160;</p>
</div>
<!-- Page 18 -->
<a name="18"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1838{font-size:17px;font-family:TimesNewRomanPSMT;color:#0000cc;}
	.ft1839{font-size:17px;line-height:21px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page18-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft183">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft180">18&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft1839"><b>PARTICULARS TO&#160;APPEAR&#160;ON&#160;THE&#160;OUTER&#160;PACKAGING&#160;<br/></b>Carton&#160;box&#160;for&#160;syringe(s)&#160;with needle:&#160;<br/>-&#160;1&#160;pre-filled syringe&#160;(0.5&#160;ml)&#160;with needle&#160;<br/>-&#160;10 pre-filled syringes&#160;(0.5&#160;ml)&#160;with needle&#160;<br/>Carton&#160;box&#160;for&#160;syringe(s)&#160;without&#160;needle:&#160;<br/>-&#160;1 pre-filled syringe&#160;(0.5&#160;ml)&#160;without&#160;needle&#160;<br/>-&#160;10 pre-filled syringes&#160;(0.5&#160;ml)&#160;without&#160;needle&#160;<br/>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:267px;left:149px;white-space:nowrap" class="ft181"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT</b>&#160;</p>
<p style="position:absolute;top:288px;left:106px;white-space:nowrap" class="ft1839">&#160;<br/>Flucelvax&#160;Tetra&#160;suspension&#160;for&#160;injection in&#160;pre-filled&#160;syringe&#160;<br/>Influenza&#160;vaccine&#160;(surface&#160;antigen,&#160;inactivated,&#160;prepared in&#160;cell&#160;cultures)&#160;<br/>2022/2023&#160;SEASON<b>&#160;<br/></b>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:404px;left:149px;white-space:nowrap" class="ft181"><b>STATEMENT&#160;OF ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft185">&#160;<br/>Influenza&#160;virus surface&#160;antigens&#160;(haemagglutinin&#160;and neuraminidase), inactivated,&#160;of&#160;the following&#160;<br/>strains*:&#160;<br/>&#160;<br/>A/Wisconsin/588/2019 (H1N1)pdm09-like strain&#160;15&#160;micrograms&#160;HA**&#160;</p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft182">A/Darwin/6/2021&#160;(H3N2)-like strain&#160;15&#160;micrograms HA**&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft182">B/Austria/1359417/2021-like strain&#160;15&#160;micrograms HA**&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft188">B/Phuket/3073/2013-like&#160;strain&#160;15&#160;micrograms HA**&#160;<br/>&#160;<br/>per&#160;0.5&#160;ml&#160;dose&#160;<br/>……………………………………….&#160;<br/>*&#160;</p>
<p style="position:absolute;top:661px;left:149px;white-space:nowrap" class="ft182">propagated&#160;in Madin Darby&#160;Canine Kidney (MDCK)&#160;cells&#160;</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft182">**&#160;</p>
<p style="position:absolute;top:680px;left:149px;white-space:nowrap" class="ft182">haemagglutinin&#160;</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft1839">&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:739px;left:149px;white-space:nowrap" class="ft181"><b>LIST&#160;OF EXCIPIENTS</b>&#160;</p>
<p style="position:absolute;top:760px;left:106px;white-space:nowrap" class="ft1839">&#160;<br/>Sodium&#160;chloride, potassium&#160;chloride,&#160;magnesium&#160;chloride&#160;hexahydrate, disodium&#160;phosphate&#160;<br/>dihydrate, potassium&#160;dihydrogen&#160;phosphate and water&#160;for&#160;injections.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:857px;left:149px;white-space:nowrap" class="ft181"><b>PHARMACEUTICAL&#160;FORM AND&#160;CONTENTS</b>&#160;</p>
<p style="position:absolute;top:879px;left:106px;white-space:nowrap" class="ft1839">&#160;<br/>Suspension&#160;for&#160;injection&#160;in&#160;pre-filled syringe&#160;<br/>&#160;<br/>10 pre-filled&#160;syringes&#160;(0.5&#160;ml)&#160;without&#160;needle&#160;<br/>1 pre-filled&#160;syringe&#160;(0.5&#160;ml)&#160;with needle&#160;<br/>10 pre-filled&#160;syringes&#160;(0.5&#160;ml)&#160;with needle&#160;<br/>1 pre-filled&#160;syringe&#160;(0.5&#160;ml)&#160;without&#160;needle&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:1071px;left:149px;white-space:nowrap" class="ft181"><b>METHOD&#160;AND&#160;ROUTE(S)&#160;OF ADMINISTRATION</b>&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft185">&#160;<br/>Intramuscular&#160;use.&#160;<br/>&#160;</p>
</div>
<!-- Page 19 -->
<a name="19"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page19-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft193">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft190">19&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1939">Read the package leaflet&#160;before&#160;use.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft1929"><b>SPECIAL&#160;WARNING THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED&#160;OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN</b>&#160;</p>
<p style="position:absolute;top:189px;left:106px;white-space:nowrap" class="ft1939">&#160;<br/>Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:267px;left:149px;white-space:nowrap" class="ft191"><b>OTHER&#160;SPECIAL&#160;WARNING(S), IF NECESSARY</b>&#160;</p>
<p style="position:absolute;top:288px;left:106px;white-space:nowrap" class="ft1939">&#160;<br/>&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:347px;left:149px;white-space:nowrap" class="ft191"><b>EXPIRY&#160;DATE</b>&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1939">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:447px;left:149px;white-space:nowrap" class="ft191"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS</b>&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1939">&#160;<br/>Store&#160;in&#160;a&#160;refrigerator.&#160;<br/>Do not&#160;freeze.&#160;<br/>Keep the pre-filled syringe&#160;in the outer&#160;carton in&#160;order&#160;to protect&#160;from&#160;light.&#160;<br/>&#160;<br/>&#160;<br/><b>10.&#160;</b></p>
<p style="position:absolute;top:584px;left:149px;white-space:nowrap" class="ft1929"><b>SPECIAL&#160;PRECAUTIONS FOR&#160;DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;<br/>OR&#160;WASTE&#160;MATERIALS DERIVED&#160;FROM SUCH&#160;MEDICINAL&#160;PRODUCTS, IF&#160;<br/>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft1939">&#160;<br/>&#160;<br/>&#160;<br/><b>11.&#160;</b></p>
<p style="position:absolute;top:702px;left:149px;white-space:nowrap" class="ft191"><b>NAME AND&#160;ADDRESS&#160;OF THE&#160;MARKETING&#160;AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:723px;left:106px;white-space:nowrap" class="ft1939">&#160;<br/>Seqirus Netherlands B.V.&#160;<br/>Paasheuvelweg 28&#160;<br/>1105BJ Amsterdam&#160;<br/>Netherlands&#160;<br/>&#160;<br/>&#160;<br/><b>12.&#160;</b></p>
<p style="position:absolute;top:858px;left:149px;white-space:nowrap" class="ft191"><b>MARKETING AUTHORISATION&#160;NUMBER(S)&#160;</b>&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1939">&#160;<br/>EU/1/18/1326/001&#160;&#160;10&#160;pre-filled syringes without&#160;needle&#160;<br/>EU/1/18/1326/002&#160;&#160;1&#160;pre-filled syringe with needle&#160;<br/>EU/1/18/1326/003&#160;&#160;10&#160;pre-filled syringes with needle&#160;<br/>EU/1/18/1326/004 1 pre filled syringe without&#160;needle&#160;<br/>&#160;<br/>&#160;<br/><b>13.&#160;</b></p>
<p style="position:absolute;top:1015px;left:149px;white-space:nowrap" class="ft191"><b>BATCH&#160;NUMBER</b>&#160;</p>
<p style="position:absolute;top:1036px;left:106px;white-space:nowrap" class="ft1939"><i>&#160;<br/></i>Lot:&#160;<br/>&#160;<br/>&#160;<br/><b>14.&#160;</b></p>
<p style="position:absolute;top:1114px;left:149px;white-space:nowrap" class="ft191"><b>GENERAL&#160;CLASSIFICATION&#160;FOR SUPPLY</b>&#160;</p>
<p style="position:absolute;top:1135px;left:106px;white-space:nowrap" class="ft195">&#160;<br/>&#160;</p>
</div>
<!-- Page 20 -->
<a name="20"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page20-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft203">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft200">20&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:112px;left:106px;white-space:nowrap" class="ft201"><b>15.&#160;</b></p>
<p style="position:absolute;top:112px;left:149px;white-space:nowrap" class="ft201"><b>INSTRUCTIONS ON USE</b>&#160;</p>
<p style="position:absolute;top:133px;left:106px;white-space:nowrap" class="ft2039">&#160;<br/>Shake before use.&#160;<br/>&#160;<br/>&#160;<br/><b>16.&#160;</b></p>
<p style="position:absolute;top:211px;left:149px;white-space:nowrap" class="ft201"><b>INFORMATION&#160;IN BRAILLE</b>&#160;</p>
<p style="position:absolute;top:231px;left:106px;white-space:nowrap" class="ft2039">&#160;<br/>Justification for&#160;not&#160;including Braille accepted.&#160;<br/>&#160;<br/>&#160;<br/><b>17.&#160;</b></p>
<p style="position:absolute;top:309px;left:160px;white-space:nowrap" class="ft201"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:329px;left:106px;white-space:nowrap" class="ft2039">&#160;<br/>2D&#160;barcode carrying the unique&#160;identifier&#160;included.&#160;<br/>&#160;<br/>&#160;<br/><b>18.&#160;</b></p>
<p style="position:absolute;top:407px;left:160px;white-space:nowrap" class="ft201"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft205">&#160;<br/>PC:&#160;&#160;<br/>SN:&#160;&#160;<br/>NN:&#160;&#160;</p>
</div>
<!-- Page 21 -->
<a name="21"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page21-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft213">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft210">21&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft2139"><b>MINIMUM PARTICULARS TO&#160;APPEAR&#160;ON&#160;SMALL&#160;IMMEDIATE&#160;PACKAGING&#160;UNITS&#160;<br/>&#160;<br/></b>Pre-filled syringe&#160;label&#160;<br/>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft211"><b>NAME OF THE&#160;MEDICINAL&#160;PRODUCT&#160;AND&#160;ROUTE(S)&#160;OF ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:212px;left:106px;white-space:nowrap" class="ft2139">&#160;<br/>Flucelvax&#160;Tetra<i>&#160;</i>injection&#160;<br/>Influenza&#160;vaccine<i>&#160;<br/></i>2022/2023&#160;SEASON&#160;<br/>&#160;<br/>IM&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:347px;left:149px;white-space:nowrap" class="ft211"><b>METHOD&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft2139">&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:427px;left:149px;white-space:nowrap" class="ft211"><b>EXPIRY&#160;DATE&#160;</b></p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft2139">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:527px;left:149px;white-space:nowrap" class="ft211"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:548px;left:106px;white-space:nowrap" class="ft2139">&#160;<br/>Lot:&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:626px;left:149px;white-space:nowrap" class="ft211"><b>CONTENTS BY&#160;WEIGHT, BY&#160;VOLUME&#160;OR&#160;BY&#160;UNIT&#160;</b></p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft2139">&#160;<br/>0.5 ml&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:726px;left:149px;white-space:nowrap" class="ft211"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft216">&#160;<br/>&#160;<br/>&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:322px;white-space:nowrap" class="ft211"><b>&#160;</b></p>
</div>
<!-- Page 22 -->
<a name="22"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page22-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft223">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft220">22&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft225">&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:518px;left:447px;white-space:nowrap" class="ft221"><b>&#160;</b></p>
<p style="position:absolute;top:537px;left:355px;white-space:nowrap" class="ft221"><b>B. PACKAGE&#160;LEAFLET&#160;</b></p>
</div>
<!-- Page 23 -->
<a name="23"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2340{font-size:17px;font-family:TimesNewRomanPSMT;color:#ff0000;}
	.ft2341{font-size:17px;line-height:15px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page23-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft233">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft230">23&#160;</p>
<p style="position:absolute;top:89px;left:303px;white-space:nowrap" class="ft231"><b>Package&#160;leaflet:&#160;Information for&#160;the&#160;user&#160;</b></p>
<p style="position:absolute;top:109px;left:447px;white-space:nowrap" class="ft236">&#160;<br/>&#160;</p>
<p style="position:absolute;top:147px;left:229px;white-space:nowrap" class="ft231"><b>Flucelvax Tetra&#160;-&#160;suspension for&#160;injection&#160;in pre-filled syringe&#160;</b></p>
<p style="position:absolute;top:165px;left:206px;white-space:nowrap" class="ft232">Influenza&#160;vaccine&#160;(surface&#160;antigen,&#160;inactivated,&#160;prepared in&#160;cell&#160;cultures)&#160;</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:209px;left:130px;white-space:nowrap" class="ft232">This&#160;medicine&#160;is subject&#160;to&#160;additional&#160;monitoring. This&#160;will&#160;allow&#160;quick&#160;identification of&#160;new&#160;</p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft235">safety&#160;information.&#160;You can&#160;help&#160;by reporting any side effects you may get. See&#160;the end of&#160;section&#160;4&#160;<br/>for&#160;how&#160;to&#160;report&#160;side effects.&#160;<br/><b>&#160;<br/>Read all&#160;of&#160;this leaflet&#160;carefully before you&#160;receive&#160;this&#160;medicine because&#160;it&#160;contains important&#160;<br/>information&#160;for&#160;you.</b>&#160;<br/>-&#160;</p>
<p style="position:absolute;top:323px;left:149px;white-space:nowrap" class="ft232">Keep this&#160;leaflet. You may&#160;need&#160;to read&#160;it&#160;again.&#160;&#160;</p>
<p style="position:absolute;top:342px;left:106px;white-space:nowrap" class="ft232">-&#160;</p>
<p style="position:absolute;top:342px;left:149px;white-space:nowrap" class="ft232">If&#160;you have any&#160;further&#160;questions,&#160;ask your&#160;doctor,&#160;pharmacist&#160;or&#160;nurse.&#160;</p>
<p style="position:absolute;top:361px;left:106px;white-space:nowrap" class="ft232">-&#160;</p>
<p style="position:absolute;top:361px;left:149px;white-space:nowrap" class="ft236">If&#160;you get&#160;any&#160;side effects, talk&#160;to your&#160;doctor,&#160;pharmacist&#160;or&#160;nurse.&#160;This includes&#160;any possible&#160;<br/>side&#160;effects not&#160;listed in&#160;this leaflet.&#160;See&#160;section 4.&#160;</p>
<p style="position:absolute;top:398px;left:106px;white-space:nowrap" class="ft235">&#160;<br/>&#160;<br/><b>What&#160;is&#160;in this&#160;leaflet&#160;<br/></b>&#160;<br/>1.&#160;</p>
<p style="position:absolute;top:475px;left:138px;white-space:nowrap" class="ft232">What&#160;Flucelvax Tetra&#160;is and what&#160;it&#160;is used&#160;for&#160;&#160;</p>
<p style="position:absolute;top:494px;left:106px;white-space:nowrap" class="ft232">2.&#160;</p>
<p style="position:absolute;top:494px;left:138px;white-space:nowrap" class="ft232">What&#160;you need&#160;to know&#160;before you&#160;receive&#160;Flucelvax&#160;Tetra&#160;&#160;</p>
<p style="position:absolute;top:513px;left:106px;white-space:nowrap" class="ft232">3.&#160;</p>
<p style="position:absolute;top:513px;left:138px;white-space:nowrap" class="ft232">How&#160;Flucelvax Tetra&#160;is given&#160;&#160;</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft232">4.&#160;</p>
<p style="position:absolute;top:532px;left:138px;white-space:nowrap" class="ft232">Possible&#160;side effects&#160;&#160;</p>
<p style="position:absolute;top:551px;left:106px;white-space:nowrap" class="ft232">5.&#160;</p>
<p style="position:absolute;top:551px;left:138px;white-space:nowrap" class="ft232">How&#160;to store&#160;Flucelvax Tetra&#160;&#160;&#160;</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft232">6.&#160;</p>
<p style="position:absolute;top:570px;left:138px;white-space:nowrap" class="ft232">Contents of&#160;the pack and other&#160;information&#160;</p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft236">&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:627px;left:149px;white-space:nowrap" class="ft231"><b>What&#160;Flucelvax Tetra</b>&#160;<b>is&#160;and&#160;what&#160;it&#160;is used&#160;for&#160;</b></p>
<p style="position:absolute;top:646px;left:106px;white-space:nowrap" class="ft235">&#160;<br/>Flucelvax&#160;Tetra&#160;is&#160;a vaccine against&#160;flu&#160;(influenza).&#160;Flucelvax Tetra&#160;is prepared&#160;in&#160;cell&#160;cultures, and,&#160;<br/>therefore,&#160;is&#160;egg-free.&#160;<br/>When&#160;a&#160;person&#160;is given the&#160;vaccine,&#160;the&#160;immune system&#160;(the body’s natural&#160;defence&#160;system)&#160;will&#160;<br/>produce its own&#160;protection&#160;against&#160;the&#160;influenza&#160;virus.&#160;None of&#160;the&#160;ingredients&#160;in the vaccine can&#160;<br/>cause&#160;flu.&#160;<br/>&#160;<br/>Flucelvax&#160;Tetra&#160;is used&#160;to prevent&#160;flu&#160;in adults and children&#160;from&#160;2&#160;years of&#160;age.&#160;<br/>&#160;<br/>The vaccine targets&#160;four&#160;strains&#160;of&#160;influenza&#160;virus following the recommendations&#160;by the&#160;World&#160;<br/>Health Organisation&#160;for&#160;the&#160;2022/2023&#160;SEASON.&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:892px;left:149px;white-space:nowrap" class="ft231"><b>What you need&#160;to know&#160;before you&#160;receive</b>&#160;<b>Flucelvax Tetra&#160;</b></p>
<p style="position:absolute;top:912px;left:106px;white-space:nowrap" class="ft2329">&#160;<br/><b>You should not&#160;receive</b>&#160;<b>Flucelvax Tetra:&#160;<br/></b>If&#160;you are allergic&#160;to:&#160;</p>
<p style="position:absolute;top:965px;left:133px;white-space:nowrap" class="ft2335">•&#160;&#160;the active&#160;ingredients or&#160;any of&#160;the other&#160;ingredients&#160;of&#160;this medicine (listed in&#160;section&#160;6)&#160;</p>
<p style="position:absolute;top:985px;left:133px;white-space:nowrap" class="ft2335">•&#160;&#160;beta-propiolactone, cetyltrimethylammonium&#160;bromide, or&#160;polysorbate&#160;80,&#160;which are&#160;trace&#160;</p>
<p style="position:absolute;top:1010px;left:160px;white-space:nowrap" class="ft232">residues from&#160;the&#160;manufacturing&#160;process.&#160;</p>
<p style="position:absolute;top:1029px;left:106px;white-space:nowrap" class="ft2341">&#160;<br/><b>Warnings and precautions&#160;&#160;<br/></b>Talk&#160;to your&#160;doctor,&#160;pharmacist&#160;or&#160;nurse&#160;before&#160;receiving&#160;Flucelvax Tetra.&#160;<br/>&#160;<br/>BEFORE receiving the vaccine<b>&#160;<br/></b>•&#160;&#160;Your&#160;doctor&#160;or&#160;nurse&#160;will&#160;make&#160;sure that&#160;appropriate&#160;medical&#160;treatment&#160;and&#160;supervision&#160;is&#160;readily&#160;</p>
<p style="position:absolute;top:1144px;left:133px;white-space:nowrap" class="ft232">available&#160;in case&#160;of&#160;a&#160;rare anaphylactic&#160;reaction&#160;(a very&#160;severe allergic&#160;reaction with symptoms&#160;</p>
</div>
<!-- Page 24 -->
<a name="24"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page24-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft243">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft240">24&#160;</p>
<p style="position:absolute;top:89px;left:133px;white-space:nowrap" class="ft245">such as difficulty in&#160;breathing, dizziness, a weak and&#160;rapid pulse and&#160;skin rash)&#160;following the&#160;<br/>administration.&#160;This reaction may&#160;occur&#160;with&#160;Flucelvax&#160;Tetra&#160;as&#160;with all&#160;vaccines&#160;that&#160;are&#160;injected.&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft2435">•&#160;&#160;You should tell&#160;your&#160;doctor&#160;if&#160;you have an&#160;acute&#160;illness&#160;associated with&#160;fever.&#160;Your&#160;doctor&#160;may&#160;</p>
<p style="position:absolute;top:147px;left:133px;white-space:nowrap" class="ft242">decide to delay your&#160;vaccination until&#160;your&#160;fever&#160;is&#160;gone.&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2435">•&#160;&#160;You&#160;should tell&#160;your&#160;doctor&#160;if&#160;your&#160;immune system&#160;is&#160;impaired, or&#160;if&#160;you are&#160;undergoing treatment&#160;</p>
<p style="position:absolute;top:186px;left:133px;white-space:nowrap" class="ft246">which affects the immune&#160;system, e.g. with&#160;medicine against&#160;cancer&#160;(chemotherapy)&#160;or&#160;<br/>corticosteroid&#160;medicines&#160;(see&#160;section “Other&#160;medicines&#160;and Flucelvax Tetra”).&#160;</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft2435">•&#160;&#160;You should tell&#160;your&#160;doctor&#160;if&#160;you have a&#160;bleeding&#160;problem&#160;or&#160;bruise&#160;easily.&#160;</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft2435">•&#160;&#160;Fainting&#160;can&#160;occur&#160;following, or&#160;even before, any needle injection, therefore&#160;tell&#160;the doctor&#160;or&#160;</p>
<p style="position:absolute;top:264px;left:133px;white-space:nowrap" class="ft242">nurse&#160;if&#160;you&#160;fainted with a&#160;previous&#160;injection.&#160;</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft245">&#160;<br/>As with&#160;all&#160;vaccines, Flucelvax Tetra&#160;may not&#160;fully&#160;protect&#160;all&#160;persons who&#160;are vaccinated.&#160;<br/>&#160;<br/><b>Other&#160;medicines&#160;and&#160;Flucelvax Tetra</b>&#160;&#160;<br/>Tell&#160;your&#160;doctor&#160;or&#160;nurse&#160;if&#160;you are using, have&#160;recently&#160;used or&#160;might&#160;use&#160;any other&#160;medicines,&#160;<br/>including medicines&#160;obtained without&#160;a prescription or&#160;if&#160;you have recently received any other&#160;<br/>vaccine.&#160;<br/>&#160;<br/>Flucelvax&#160;Tetra&#160;may&#160;be given at&#160;the&#160;same&#160;time&#160;as&#160;other&#160;vaccines.&#160;<br/>&#160;<br/><b>Pregnancy&#160;and&#160;breast-feeding&#160;&#160;<br/></b>Pregnancy:&#160;<br/>Tell&#160;your&#160;doctor&#160;if&#160;you are&#160;pregnant,&#160;think you may be&#160;pregnant&#160;or&#160;are&#160;planning&#160;to&#160;have&#160;a&#160;baby.&#160;<br/>Influenza&#160;vaccines&#160;may be&#160;given&#160;in any trimester&#160;of&#160;pregnancy.&#160;&#160;<br/>&#160;<br/>Breast-feeding:&#160;<br/>Use&#160;of&#160;Flucelvax Tetra&#160;during breast-feeding has&#160;not&#160;been studied.&#160;Flucelvax&#160;Tetra may be&#160;given&#160;<br/>during&#160;breast-feeding.&#160;<br/>&#160;<br/><b>Driving and&#160;using&#160;machines&#160;<br/></b>Flucelvax&#160;Tetra&#160;has&#160;no&#160;or&#160;negligible&#160;effect&#160;on your&#160;ability&#160;to drive and&#160;use&#160;machines.&#160;<br/>&#160;<br/><b>Flucelvax Tetra</b>&#160;<b>contains&#160;sodium&#160;chloride and&#160;potassium&#160;chloride</b>&#160;<br/>This&#160;vaccine&#160;contains less&#160;than 1&#160;mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;dose, i.e. essentially ‘sodium&#160;free’.&#160;<br/>This&#160;vaccine&#160;contains potassium, less&#160;than 1&#160;mmol&#160;(39&#160;mg)&#160;per&#160;dose,&#160;i.e. essentially ‘potassium&#160;free’.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:798px;left:149px;white-space:nowrap" class="ft241"><b>How&#160;Flucelvax Tetra</b>&#160;<b>is given&#160;</b></p>
<p style="position:absolute;top:816px;left:106px;white-space:nowrap" class="ft246">&#160;<br/>Flucelvax&#160;Tetra&#160;is given to&#160;you by your&#160;doctor&#160;or&#160;nurse&#160;as&#160;an&#160;injection into&#160;the&#160;muscle&#160;at&#160;the&#160;top&#160;of&#160;the&#160;<br/>upper&#160;arm&#160;(deltoid&#160;muscle).&#160;<br/>&#160;<br/>Adults&#160;and&#160;children&#160;from&#160;2&#160;years&#160;of&#160;age:&#160;<br/>&#160;<br/>One dose&#160;of&#160;0.5&#160;ml&#160;<br/>&#160;<br/>If&#160;your&#160;child is younger&#160;than 9&#160;years of&#160;age and&#160;has&#160;not&#160;been previously vaccinated&#160;against&#160;flu, a&#160;<br/>second&#160;dose&#160;should be given after&#160;at&#160;least&#160;4 weeks.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:1044px;left:149px;white-space:nowrap" class="ft241"><b>Possible&#160;side&#160;effects</b>&#160;</p>
<p style="position:absolute;top:1063px;left:106px;white-space:nowrap" class="ft245">&#160;<br/>Like&#160;all&#160;medicines,&#160;this medicine&#160;can cause&#160;side effects, although not&#160;everybody gets&#160;them.&#160;<br/>The following side&#160;effects&#160;have&#160;been&#160;reported&#160;during&#160;clinical&#160;trials and&#160;during general&#160;use:&#160;<br/>&#160;</p>
</div>
<!-- Page 25 -->
<a name="25"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2542{font-size:17px;font-family:BCDFEE+Verdana;color:#000000;}
-->
</style>
<div id="page25-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft253">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft250">25&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft257"><b>Very serious side effects&#160;<br/></b>Tell&#160;your&#160;doctor&#160;immediately or&#160;go to the casualty&#160;department&#160;at&#160;your&#160;nearest&#160;hospital&#160;if&#160;you&#160;<br/>experience&#160;the&#160;following side effect&#160;–&#160;you&#160;may need urgent&#160;medical&#160;attention&#160;or&#160;hospitalisation:&#160;<br/>&#160;<br/>•&#160;&#160;Difficulty&#160;in&#160;breathing, dizziness, a&#160;weak and rapid pulse&#160;and&#160;skin rash which are&#160;symptoms of&#160;an&#160;</p>
<p style="position:absolute;top:184px;left:128px;white-space:nowrap" class="ft252">anaphylactic reaction (a very severe&#160;allergic&#160;reaction)&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft257">&#160;<br/><b>Serious side effects&#160;<br/></b>Tell&#160;your&#160;doctor&#160;immediately if&#160;you&#160;experience&#160;any of&#160;the&#160;following side effects&#160;–&#160;you may need&#160;<br/>medical&#160;attention:&#160;<br/>&#160;<br/>•&#160;&#160;You feel&#160;weak, you have&#160;difficulty&#160;moving&#160;around or&#160;you experience&#160;numbness&#160;or&#160;tingling in your&#160;</p>
<p style="position:absolute;top:317px;left:128px;white-space:nowrap" class="ft257">limbs. These can&#160;be symptoms of&#160;&#160;Guillain-Barré&#160;syndrome&#160;(GBS), an&#160;autoimmune disease caused&#160;<br/>by your&#160;body’s own&#160;immune system.&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft255">•&#160;&#160;Extensive&#160;swelling of&#160;injected limb&#160;<br/>&#160;<br/><b>Mild side effects&#160;<br/></b>Very common&#160;(may&#160;affect&#160;more than 1&#160;in 10&#160;people):&#160;<br/>•&#160;&#160;Injection&#160;site pain,&#160;bruising,&#160;reddening&#160;and&#160;hardening&#160;or&#160;swelling at&#160;the site of&#160;the&#160;injection&#160;<br/>•&#160;&#160;Headache&#160;<br/>•&#160;&#160;Muscle pain&#160;&#160;&#160;<br/>•&#160;&#160;Tiredness&#160;&#160;<br/>•&#160;&#160;Loss of&#160;appetite&#160;<br/>•&#160;&#160;Irritability&#160;(only reported&#160;in&#160;children from&#160;2 to &lt; 6 years)&#160;<br/>•&#160;&#160;Sleepiness&#160;(only reported&#160;in&#160;children&#160;2&#160;to &lt;&#160;6&#160;years)&#160;<br/>Hardening or&#160;swelling&#160;at&#160;the site of&#160;the&#160;injection,&#160;headache,&#160;muscle pain,&#160;and&#160;tiredness&#160;were common&#160;<br/>in the elderly.&#160;<br/>Bruising&#160;at&#160;the&#160;site of&#160;the injection was&#160;common&#160;in adults,&#160;eldery&#160;and&#160;children 9&#160;to&#160;&lt; 18 years.&#160;<br/>Headache was&#160;common&#160;in&#160;the elderly.&#160;<br/>Loss of&#160;appetite&#160;was&#160;common in&#160;adults,&#160;eldery&#160;and children 9&#160;to&#160;&lt; 18 years.&#160;<br/>&#160;<br/>Common&#160;(may&#160;affect&#160;up&#160;to&#160;1 in 10&#160;people):&#160;<br/>•&#160;&#160;Nausea,&#160;vomiting,&#160;diarrhoea&#160;&#160;<br/>•&#160;&#160;Joint&#160;pain&#160;<br/>•&#160;&#160;Shivering&#160;<br/>•&#160;&#160;Change&#160;in eating habits&#160;(only reported&#160;in&#160;children from&#160;2 to &lt;&#160;6 years)&#160;<br/>•&#160;&#160;Fever&#160;(&gt;&#160;38°C)&#160;<br/>Vomiting was&#160;uncommon in the&#160;elderly.&#160;<br/>Fever&#160;was uncommon&#160;in&#160;adults and&#160;the&#160;elderly.&#160;<br/>&#160;<br/>Not&#160;known&#160;(frequency&#160;cannot&#160;be&#160;estimated&#160;from&#160;the&#160;available data):&#160;<br/>•&#160;&#160;Numbness&#160;and tingling sensation&#160;(paraesthesia)&#160;<br/>•&#160;&#160;Generalised&#160;skin&#160;reactions including&#160;itching, bumps&#160;on&#160;the skin&#160;(pruritis, urticaria)&#160;or&#160;non-specific&#160;</p>
<p style="position:absolute;top:905px;left:128px;white-space:nowrap" class="ft252">rash&#160;&#160;</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft255">&#160;<br/><b>Reporting of&#160;side effects&#160;<br/></b>If&#160;you get&#160;any&#160;side effects,&#160;talk&#160;to your&#160;doctor, pharmacist&#160;or&#160;nurse.&#160;This includes&#160;any possible&#160;side&#160;<br/>effects not&#160;listed&#160;in&#160;this leaflet.&#160;You&#160;can&#160;also report&#160;side effects directly&#160;via&#160;the&#160;national&#160;reporting&#160;<br/>system&#160;listed i<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">n&#160;Appendix&#160;V.</a>*&#160;By reporting&#160;side effects,&#160;you can&#160;help provide more information on&#160;the&#160;<br/>safety of&#160;this&#160;medicine.&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:1076px;left:149px;white-space:nowrap" class="ft251"><b>How&#160;to&#160;store&#160;Flucelvax Tetra</b>&#160;<b>&#160;</b></p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft256">&#160;<br/>Keep&#160;this&#160;vaccine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;<br/>&#160;<br/>Store&#160;in&#160;a refrigerator&#160;(2 °C&#160;to&#160;8 °C). Do not&#160;freeze.&#160;</p>
</div>
<!-- Page 26 -->
<a name="26"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page26-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft263">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft260">26&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft266">Keep the pre-filled syringe&#160;in the outer&#160;carton in&#160;order&#160;to protect&#160;from&#160;light.&#160;<br/>&#160;<br/>Do not&#160;use&#160;this&#160;vaccine&#160;after&#160;the expiry&#160;date which is stated&#160;on the label&#160;and&#160;carton&#160;after&#160;EXP. The&#160;<br/>expiry date&#160;refers to&#160;the last&#160;day of&#160;that&#160;month.&#160;<br/>&#160;<br/>Do not&#160;throw&#160;away any&#160;medicines&#160;via wastewater&#160;or&#160;household waste. Ask your&#160;pharmacist&#160;how&#160;to&#160;<br/>throw&#160;away&#160;medicines&#160;you&#160;no longer&#160;use. These&#160;measures&#160;will&#160;help protect&#160;the&#160;environment.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:260px;left:149px;white-space:nowrap" class="ft261"><b>Contents of&#160;the pack and&#160;other&#160;information&#160;</b></p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft265">&#160;<br/><b>What&#160;Flucelvax Tetra</b>&#160;<b>contains&#160;&#160;<br/></b>&#160;<br/>The active substances are&#160;influenza&#160;virus&#160;surface antigens&#160;(haemagglutinin and neuraminidase),&#160;<br/>inactivated, of&#160;the following strains*:&#160;<br/>&#160;<br/>A/Wisconsin/588/2019 (H1N1)pdm09-like strain&#160;(A/Delaware/55/2019 CVR-45)&#160;15&#160;micrograms&#160;<br/>HA**&#160;</p>
<p style="position:absolute;top:440px;left:106px;white-space:nowrap" class="ft262">A/Darwin/6/2021&#160;(H3N2)-like&#160;strain&#160;(A/Darwin/11/2021,&#160;wild type)&#160;15&#160;micrograms HA**&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft262">B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type)&#160;15&#160;micrograms HA**&#160;</p>
<p style="position:absolute;top:496px;left:106px;white-space:nowrap" class="ft268">B/Phuket/3073/2013-like&#160;strain&#160;(B/Singapore/INFTT-16-0610/2016, wild type)&#160;15&#160;micrograms HA**&#160;<br/>&#160;<br/>per&#160;0.5&#160;ml&#160;dose&#160;<br/>……………………………………….&#160;<br/>*&#160;</p>
<p style="position:absolute;top:571px;left:149px;white-space:nowrap" class="ft265">propagated&#160;in Madin Darby&#160;Canine Kidney (MDCK)&#160;cells (this is the special&#160;cell&#160;culture&#160;in&#160;<br/>which&#160;the&#160;influenza&#160;virus is&#160;grown);&#160;&#160;</p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft262">**&#160;</p>
<p style="position:absolute;top:609px;left:149px;white-space:nowrap" class="ft262">haemagglutinin&#160;</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft265">&#160;<br/>This&#160;vaccine&#160;complies&#160;with&#160;the&#160;World Health Organisation&#160;(WHO)&#160;recommendation (northern&#160;<br/>hemisphere)&#160;and EU&#160;recommendation&#160;for&#160;the&#160;2022/2023&#160;SEASON.&#160;<br/>&#160;<br/>The other&#160;ingredients are:&#160;sodium&#160;chloride, potassium&#160;chloride, magnesium&#160;chloride hexahydrate,&#160;<br/>disodium&#160;phosphate dihydrate, potassium&#160;dihydrogen&#160;phosphate&#160;and water&#160;for&#160;injections.&#160;<br/>&#160;<br/><b>What&#160;Flucelvax Tetra&#160;looks like and contents of&#160;the&#160;pack&#160;<br/></b>&#160;<br/>Flucelvax&#160;Tetra&#160;is&#160;a suspension&#160;for&#160;injection in&#160;a pre-filled syringe (ready to&#160;use&#160;syringe).&#160;&#160;<br/>Flucelvax&#160;Tetra&#160;is&#160;a clear&#160;to&#160;slightly opalescent&#160;suspension.&#160;<br/>A&#160;single syringe contains 0.5&#160;ml&#160;of&#160;suspension for&#160;injection.&#160;<br/>Flucelvax&#160;Tetra&#160;is&#160;available&#160;in packs&#160;containing&#160;1&#160;pre-filled syringe&#160;with&#160;or&#160;without&#160;needle&#160;or&#160;10 pre-<br/>filled syringes&#160;with or&#160;without&#160;needles.&#160;<br/>Not&#160;all&#160;pack sizes&#160;may be&#160;marketed.&#160;<br/>&#160;<br/><b>Marketing&#160;Authorisation&#160;Holder&#160;&#160;<br/></b>Seqirus Netherlands B.V.&#160;<br/>Paasheuvelweg 28&#160;<br/>1105BJ Amsterdam&#160;<br/>Netherlands&#160;<br/>&#160;<br/><b>Manufacturer&#160;<br/></b>Seqirus Netherlands B.V.&#160;<br/>Paasheuvelweg 28&#160;<br/>1105BJ Amsterdam&#160;<br/>Netherlands&#160;<br/>&#160;</p>
</div>
<!-- Page 27 -->
<a name="27"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2743{font-size:17px;font-family:TimesNewRomanPSMT;color:#1f487c;}
	.ft2744{font-size:17px;line-height:16px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft2745{font-size:17px;line-height:22px;font-family:TimesNewRomanPS;color:#000000;}
	.ft2746{font-size:17px;line-height:23px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft2747{font-size:17px;line-height:23px;font-family:TimesNewRomanPS;color:#000000;}
	.ft2748{font-size:17px;line-height:19px;font-family:TimesNewRomanPSMT;color:#1f487c;}
-->
</style>
<div id="page27-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft273">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft270">27&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft275">For any&#160;information about&#160;this&#160;medicine, please&#160;contact&#160;the local&#160;representative of&#160;the&#160;Marketing&#160;<br/>Authorization Holder:&#160;<br/>&#160;</p>
<p style="position:absolute;top:148px;left:115px;white-space:nowrap" class="ft277"><b>België/Belgique/Belgien&#160;<br/></b>Seqirus Netherlands B.V.Nederland/Netherlands&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>България&#160;<br/></b>Seqirus Netherlands B.V.&#160;Нидерландия&#160;<br/>Тел.:&#160;+31 (0)&#160;20&#160;204 6900&#160;<br/>&#160;<br/><b>Česká&#160;republika&#160;<br/></b>Seqirus Netherlands B.V.&#160;Nizozemsko&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Danmark&#160;<br/></b>Seqirus Netherlands B.V.&#160;Holland&#160;<br/>Tlf:&#160;+31&#160;(0)&#160;20 204&#160;6900&#160;<br/>&#160;<br/><b>Deutschland&#160;<br/></b>Seqirus GmbH&#160;Marburg&#160;<br/>Tel:&#160;08003601010&#160;<br/>&#160;<br/><b>Eesti&#160;<br/></b>Seqirus Netherlands B.V.&#160;Holland&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Ελλάδα&#160;<br/></b>Seqirus Netherlands B.V.&#160;Ολλανδία&#160;<br/>Τηλ:&#160;+31 (0)&#160;20&#160;204 6900&#160;<br/>&#160;<br/><b>España&#160;<br/></b>Seqirus Spain, S.L., Barcelona&#160;<br/>Tel:&#160;937 817 884&#160;<br/>&#160;<br/><b>France&#160;<br/></b>Seqirus Netherlands B.V.&#160;Netherlands&#160;<br/>Tél:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Hrvatska&#160;<br/></b>Seqirus Netherlands B.V.&#160;Nizozemska&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Ireland&#160;<br/></b>Seqirus UK&#160;Limited&#160;Maidenhead&#160;<br/>Tel:&#160;+44 1628 641&#160;500&#160;<br/>&#160;<br/><b>Ísland&#160;<br/></b>Seqirus Netherlands B.V.&#160;Holland&#160;<br/>Sími:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Italia&#160;<br/></b>Seqirus S.r.l.&#160;Siena&#160;<br/>Tel:&#160;+39&#160;0577 096400&#160;<br/>&#160;<br/><b>Κύπρος&#160;</b></p>
<p style="position:absolute;top:148px;left:455px;white-space:nowrap" class="ft275"><b>Lietuva&#160;<br/></b>Seqirus Netherlands B.V.&#160;Nyderlandai&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Luxembourg/Luxemburg&#160;<br/></b>Seqirus Netherlands B.V.&#160;Netherlands&#160;<br/>Tél/Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Magyarország&#160;<br/></b>Seqirus Netherlands B.V.&#160;Hollandia&#160;<br/>Tel.:&#160;+31&#160;(0)&#160;20 204&#160;6900&#160;<br/>&#160;<br/><b>Malta&#160;<br/></b>Seqirus Netherlands B.V.&#160;In-Netherlands&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Nederland&#160;<br/></b>Seqirus Netherlands B.V.&#160;Amsterdam&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Norge&#160;<br/></b>Seqirus Netherlands B.V.&#160;Nederland&#160;<br/>Tlf:&#160;+31&#160;(0)&#160;20 204&#160;6900&#160;<br/>&#160;<br/><b>Österreich&#160;<br/></b>Valneva Austria GmbH, Wien&#160;<br/>Tel:&#160;+43 1&#160;20620&#160;&#160;<br/>&#160;<br/><b>Polska&#160;<br/></b>Seqirus Netherlands B.V.&#160;Holandia&#160;<br/>Tel.:&#160;+31&#160;(0)&#160;20 204&#160;6900&#160;<br/>&#160;<br/><b>Portugal&#160;<br/></b>Seqirus Netherlands B.V.&#160;Países Baixos&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>România&#160;<br/></b>Seqirus Netherlands B.V.&#160;Olanda&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Slovenija&#160;<br/></b>Seqirus Netherlands B.V.&#160;Nizozemska&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Slovenská&#160;republika&#160;<br/></b>Seqirus Netherlands B.V.&#160;Holandsko&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Suomi/Finland&#160;<br/></b>Seqirus Netherlands B.V.&#160;Alankomaat&#160;<br/>Puh/Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;<br/><b>Sverige&#160;</b></p>
</div>
<!-- Page 28 -->
<a name="28"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page28-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:60px;left:106px;white-space:nowrap" class="ft283">&#160;</p>
<p style="position:absolute;top:1195px;left:436px;white-space:nowrap" class="ft280">28&#160;</p>
<p style="position:absolute;top:89px;left:115px;white-space:nowrap" class="ft285">Seqirus Netherlands B.V.&#160;Ολλανδία&#160;<br/>Τηλ:&#160;+31 (0)&#160;20&#160;204 6900&#160;<br/>&#160;<br/><b>Latvija&#160;<br/></b>Seqirus Netherlands B.V.&#160;Nīderlande&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204 6900&#160;<br/>&#160;</p>
<p style="position:absolute;top:89px;left:455px;white-space:nowrap" class="ft285">Seqirus Netherlands B.V.&#160;Nederländerna&#160;<br/>Tel:&#160;+31&#160;(0)&#160;20 204&#160;6900&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft286">&#160;<br/><b>&#160;<br/>This&#160;leaflet&#160;was&#160;last&#160;revised in.&#160;<br/></b>&#160;<br/><b>Other sources of&#160;information&#160;<br/></b>&#160;<br/>Detailed&#160;information on&#160;this medicine&#160;is&#160;available on&#160;the European&#160;Medicines Agency web&#160;site:&#160;<br/>http://www.ema.europa.eu.&#160;&#160;<br/>&#160;<br/>---------------------------------------------------------------------------------------------------------------------------&#160;<br/>The following&#160;information&#160;is intended&#160;for&#160;healthcare professionals only:&#160;<br/>&#160;<br/>Appropriate&#160;medical&#160;treatment&#160;and supervision&#160;should&#160;always&#160;be&#160;readily available&#160;in case&#160;of&#160;a&#160;rare&#160;<br/>anaphylactic event&#160;following the&#160;administration of&#160;the&#160;vaccine.&#160;<br/>&#160;<br/>Shake before use. After&#160;shaking,&#160;the normal&#160;appearance of&#160;the vaccine&#160;is&#160;a clear&#160;to&#160;slightly opalescent&#160;<br/>suspension.&#160;<br/>&#160;<br/>The vaccine should be visually inspected&#160;for&#160;particulate matter&#160;and discoloration&#160;prior&#160;to&#160;<br/>administration.&#160;In the&#160;event&#160;of&#160;any&#160;foreign particulate&#160;matter&#160;and/or&#160;variation of&#160;physical&#160;aspect&#160;being&#160;<br/>observed, do not&#160;administer&#160;the vaccine.&#160;<br/>&#160;</p>
</div>
<a name="outline"></a><h1>Document Outline</h1>
<ul>
<li><a href="flucelvax-tetra-epar-product-information_en.html#1">SUMMARY OF PRODUCT CHARACTERISTICS</a></li>
<li><a href="flucelvax-tetra-epar-product-information_en.html#15">A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</a></li>
<li><a href="flucelvax-tetra-epar-product-information_en.html#15">B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</a></li>
<li><a href="flucelvax-tetra-epar-product-information_en.html#15">C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</a></li>
<li><a href="flucelvax-tetra-epar-product-information_en.html#15">D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</a></li>
<li><a href="flucelvax-tetra-epar-product-information_en.html#17">A. LABELLING</a></li>
<li><a href="flucelvax-tetra-epar-product-information_en.html#22">B. PACKAGE LEAFLET</a></li>
</ul>
<hr/>
</body>
</html>
